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Recent biomedical literature has proposed that the Endothelial-Mesenchymal Transition 
(EndMT) is a critical cellular process involved in the pathophysiology of a number of 
diseases, including cardiovascular conditions such as atherosclerosis and cardiac fibrosis. 
Classified as a subtype of Epithelial-Mesenchymal Transition (EMT) due to similarities 
in molecular events, EndMT is characterized by endothelial cells (ECs) turning into a 
different cell lineage through suppression of endothelial-specific genes and activation of 
mesenchymal-specific ones.  Members of the Transforming Growth Factor β (TGFβ) 
superfamily have been shown to play a major role in the initiation of this process. 
HDAC3α, an alternative splicing isoform of the mouse gene HDAC3, has been previously 
found to be involved in the EndMT. Through the overexpression of HDAC3α in human 
ECs and a pressure-overload mouse model, the present research project aimed at 
characterizing the molecular mechanisms underlying the function of HDAC3α in EndMT 
and its role in cardiac fibrosis. Results indicate that HDAC3α induces an EndMT 
phenotype through the upstream activation of TGFβ signalling, a mechanism that is 
potentially mediated by increased secretion of proteases. Furthermore, HDAC3α 
expression is increased in fibrotic hearts but its direct role in EndMT in vivo needs further 
investigation.  
Subsequently,  experiments aiming at modelling the EndMT in vitro in human ECs 
revealed that EndMT-like responses (morphological changes, altered gene/protein 
expression) were induced by inflammatory cytokines, with little evidence of the typical 
endothelial markers-DOWN/mesenchymal markers-UP molecular pattern triggered by 
TGFβ ligands. Further cellular and molecular data led to interpret the phenotypic changes 
of ECs in vitro as inflammatory-induced responses such as vascular leakage and 
angiogenic-healing, rather than a differentiation into a distinct cell type. Taken together, 
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Chapter I - Introduction 
 
 
1.1 The Endothelium 
 
 
1.1.1 Evolution of the endothelium 
 
All complex metazoans share an internal system for pumping fluids throughout the body 
and its general organization varies greatly across different species. This difference ranges 
from the open and low-pressure circulation of invertebrates to the closed, high-pressure 
systems of vertebrates. The key selective pressures that determine the evolution of these 
systems are the physico-chemical properties of oxygen diffusion  into the cells and the 
removal of waste (1). The complex cardiovascular systems of vertebrates thus evolve in 
response to increasing animal size and metabolic demand. Less intuitive is why the 
endothelial cells (ECs) evolved. Different hypotheses have been put forward in this 
regard. One possibility is that an endothelial lining serves as a barrier to prevent the loss 
of plasma proteins, which are necessary to maintain a balance between the osmotic and 
the hydrostatic pressures (2). Another suggestion is that the ECs are derived from a 
specialized type of blood cell found in invertebrates, the amoebocyte. Through a process 
of “epithelialization”,  this mobile cell could have formed a proto-endothelial cell whose 
primary functions, consistent with this origin, would have been immunological 
cooperation and regulation of vascular growth (3).  Nevertheless, speculations about the 
evolution of the endothelium are difficult to formulate because ECs have evolved a 
number of different functions. It is likely that multiple and concurrent explanations 
account for its evolutionary history. Answering these questions will provide important 
insight into not only the function of endothelium but also its physiological interplay with 











1.1.2 Development of the endothelium 
 
The endothelial lineage derives from mesodermal progenitors called angioblasts or 
hemangioblasts, since these precursors have also been shown to give rise to the 
hematopoietic cells (5). During early development, these progenitor cells migrate 
throughout the embryo to give rise the both intraembryonic vasculature and the 
extraembryonic endothelium of the yolk sac, which together will be part of the vitelline 
circulation. 
In the yolk sac the angioblasts form cell aggregates called blood islands. The outer layer 
of these structures will subsequently differentiate into ECs while internal cells will form 
hematopoietic cells. On the other hand, during the intraembryonic vascular development 
the angioblasts follow a different differentiation pathway as they give rise to both 
endothelial and cardiac lineages (6). The endocardial tubes, the precursors of the heart, 
are indeed formed by both ECs and myocytes (see section 1.3.1).  
The de-novo formation of blood vessels involves the migration and coalescence of 
angioblasts, a process termed vasculogenesis. In vertebrate development, the dorsal aorta 
and the cardinal vein are the first blood vessels to be formed (7). Following 
vasculogenesis, the expansion and definition of the vascular network proceed through the 
“angiogenesis”, i.e., the growth of new blood vessels from pre-existing ones (Figure 1) 
(8). Angiogenesis is a multistep process that requires coordinated cellular activities by 
ECs such as migration, cell division, survival and lumen formation. The early events that 
characterise the initiation of angiogenesis have been described by the “tip-stalk” cellular 
model (9), which identifies two distinct EC phenotypes in a nascent angiogenic sprout 
(Figure 2). Tip cells are polarized and migratory cells that emerge from a quiescent 
endothelial monolayer and guide the formation of a new vessel branch. Increased 
filopodia formation and secretion of proteases allow tip cells to degrade the surrounding 
basement membrane and to explore the extracellular space. On the other hand, stalk cells 
trail behind tip cells in a nascent endothelial sprout. They proliferate in order to extend 
the vessel and form the vascular lumen. Importantly, the emergence of tip and stalk 
phenotypes is not pre-determined; ECs can in fact dynamically compete for either 
positions as a consequence of several genetic and environmental cues (10). Once formed, 
sprouts of different vessels can then fuse together (anastomosis) and will establish a 
continuous lumen to allow blood flow circulation. Subsequently, the nascent vasculature 
requires maturations steps involving the production of a basement membrane and the 
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recruitment of supporting mural cells (e.g. smooth muscle cells and pericytes) (11). 
 
Several signalling pathways such as Angiopoietin-Tie and Notch have been shown to 
control different aspects of vascular development (12, 13). However, the most 
characterised master regulators of both vasculogenesis and angiogenesis are the Vascular 
Endothelial Growth Factors (VEGFs) (14). VEGF family includes five different 
members: VEGF-A, VEGF-B, VEGF-C, VEGF-D and PGF (placental growth factor). 
VEGFs bind to two tyrosine-kinase receptors, VEGFR-1 (flt-1) and VEGFR-2 (KDR/flk-
1) and activate multiple downstream signals that regulate different behaviours of ECs 
during angiogenesis. The ability of VEGFs to induce diverse responses is not only due to 
the presence of multiple genes but also to the different isoforms generated by alternative 
splicing (15). The production and secretion of VEGFs, and thus the initial activation of 
vasculogenesis and angiogenesis, are induced by hypoxia: in low oxygen concentrations, 
cells of different tissues produce the Hypoxia-inducible factor (HIF), a transcription 
factor that induce the expression of VEGF (16). Therefore, in both development and 
disease, this general mechanism directs the angiogenic growth towards oxygen-deficient 
tissues in order to restore the appropriate blood circulation.  
Further details on the molecular mechanisms of angiogenesis can be found in the 


























Figure 1: Vasculogenesis and angiogenesis during vascular development. The figure 
illustrates the sequential steps of vascular development. During vasculogenesis, angioblasts can 
either assemble into blood islands and a primitive plexus, or form the first intraembryonic vessels: 
dorsal aorta and cardinal vein. Subsequently, angiogenesis expands these primitive structures 





















Figure 2: Tip and Stalk endothelial cells in angiogenesis. Pro-angiogenic factors such as VEGF 
induces the sprouting of quiescent blood vessels. Two different endothelial phenotypes will 
emerge during this process: the tip cell is the exploratory and migratory the guide the sprout 
whereas stalk cells proliferate to increase its length. The figure is adapted from Gaudens et al. (9). 
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1.1.3 Functions of the endothelium 
 
There are five general types of blood vessels in the human body, according to their size: 
arteries, arterioles, capillaries, venules and veins. Arteries are strong and elastic vessels 
that carry oxygenated blood away from the heart at high pressure. The arteries branch into 
thinner arterioles which in turn are connected to the capillaries, the smallest type of blood 
vessel, where there is the exchange of gases and nutrients to the surrounding tissues. 
Venules link the capillaries to veins, which carry blood back to the heart. Each blood 
vessel type presents a different composition of cellular layers beyond the endothelium. 
Arteries and arterioles are characterised by multiple layers of connective and muscular 
tissue (e.g. fibroblasts and smooth muscle cells), which are necessary to withstand and 
regulate high pressured blood flow. Venules and veins are also surrounded by these 
cellular layers, although to a lesser extent given the much lower blood pressure in these 
vessels. On the other hand, capillaries are composed almost exclusively of ECs. This 
feature maximizes their permeability to gases and fluids.  
The histological diversity of the blood vessels results in an high heterogeneity of 
endothelial cell structure and function (17). For instance, the endothelium can be 
structurally classified as continuous or discontinuous. In continuous endothelium, which 
characterises most of the arteries and veins as well as the capillaries of certain tissues, 
ECs are tightly connected and associated with a continuous layer of basement membrane. 
Continuous endothelium can be fenestrated or non-fenestrated. Fenestrae are circular 
transcellular pores of about 70nm in diameter and are mainly located in endothelia with 
active filtration and transport functions, such as glands and gastrointestinal mucosa. 
Discontinuous or sinusoidal endothelium, mainly found in organs like liver and bone 
marrow, lacks a basement membrane and presents larger fenestrae (18). The structural 
diversity of endothelium in different blood vessels reflects the multiple roles that ECs 
play within the cardiovascular system. These functions can be schematically grouped into 








1.1.3.1 Barrier function 
 
The endothelium has a central role in regulating tissue homeostasis. It is often described 
as a semi-permeable barrier, for it selectively allows certain molecules, e.g. plasma 
proteins, solutes, immune cells, to pass through it. The semi-permeable barrier function 
is actively regulated by ECs through different mechanisms. In general, two types of 
endothelial transport have been described: paracellular and transcellular pathways (19). 
The paracellular route is controlled by the junctional structures that maintain the tight 
cell-cell contacts in the endothelial monolayers. Examples of these intercellular junctions 
are adherens (AJs) and tight junctions (TJs). The AJs’ main component is vascular 
endothelial (VE-) cadherin. VE-cadherin is a transmembrane calcium-dependent 
glycoprotein characterised by homophilic binding. VE-cadherin is essential for regulating 
the integrity of adherens junction and thus endothelial permeability. It also plays an 
indispensable role in the correct development of the vascular system (20). TJs are cellular 
structures which include adhesive proteins such as occludins, claudins and JAMs 
(junction adhesion molecules). TJs help regulating paracellular permeability, although 
their role seems to be secondary to AJs (21). In normal conditions, AJs and TJs restrict 
the passage of solutes larger than 3 nm in radius. Their function is nevertheless very 
dynamic. Different external stimuli, such as inflammatory cytokines, can in fact promptly 
increase endothelial permeability through biochemical regulation of intercellular 
junctions (22).  
Transcellular pathways involve the selective transport of macromolecules (e.g. albumin, 
insulin and lipids) through the cell cytoplasm, a process termed transcytosis. This type of 
transport is characterised by energy-dependent vesicle trafficking and is receptor-
mediated. Caveolae, plasma membrane invaginations 50 to 100 nm in diameter, are the 
main cellular structures that mediate transcytosis in ECs (23).  
In conclusion, regulation of the endothelial barrier function is achieved through both 
transcellular and paracellular pathways. These transport mechanisms are finely regulated 
through structural and molecular processes and respond specifically according to the 
different vascular regions. A functioning endothelial barrier has a key role in homeostatic 





1.1.3.2 Vasodilation/blood flow regulation 
 
To meet the metabolic demands of different tissues, the cardiovascular system adjusts 
blood flow through the relaxation/constriction of smooth muscle cells that surround blood 
vessels. The endothelium, being in direct contact with circulating blood, is the first tissue 
that “senses” the physical forces generated by blood flow. This hemodynamic force acts 
on the endothelium as shear stress and tensile strain, which are converted by ECs into 
molecular signals towards the vessel wall. This phenomenon is collectively known as 
mechanotransduction. A multiplicity of molecular mechanisms account for this type of 
response and current opinion is that the entire endothelial cytoskeleton functions as a 
mechanotransducer rather than signalling through the actions of individual membrane 
receptors. Downstream of these “sensing” mechanisms, several biochemical signals are 
generated by the endothelium to relax blood vessels. An example of a well-established 
vasodilation factor is nitric oxide (NO), a signalling molecule that mediates several 
cellular processes in both animals and plants (24). NO is synthesized in ECs from L-
arginine by the enzyme NOS3, also known as eNOS (endothelial nitric oxide synthase), 
which is one of the three tissue-specific NOS isoforms together with NOS1 (nNOS; 
neuronal) and NOS2 (iNOS; inducible, involved in immune responses). With respect to 
endothelium-mediated vascular relaxation, the general signalling function of NO is to 
bind and activate its receptor present on smooth muscle cells (SMCs), soluble guanylyl 
cyclase (sGC). sCG activation leads to the synthesis of cyclic guanosine monophosphate 
(cGMP) which in turn functions as a second messenger, activating ion channels and 
intracellular protein kinases. When triggered in SMCs this signalling cascade has the 
















1.1.3.3 Blood coagulation/haemostasis 
 
Another illustrative example of how blood and endothelium functionally interact is 
haemostasis, namely the primary defence process that prevents vascular bleeding. This 
response has been divided into two sequential steps. Primary events include the 
recruitment of platelets and their aggregation, while the secondary processes comprise 
blood coagulation or fibrin formation (25). A pivotal ligand in primary haemostasis is Von 
Willebrand factor (vWF), a multimeric glycoprotein stored in endothelial-specific 
organelles called Weibel–Palade bodies (26). The peculiar length and domain architecture 
of vWF are indicative of its function. It is able to bind different proteins thus providing 
an adhesive bridge between platelets and the subendothelial collagen proteins that 
become exposed to blood flow upon vascular injury. The formation of an initial platelet 
plug is soon followed by blood coagulation, which characterises the secondary response 
(27). The coagulation cascade involves a complex series of enzymatic reactions among 
13 different coagulation factors. Following endothelial damage, coagulation is first 
triggered by the binding between tissue factor (TF) and Factor VII, which are located in 
the subendothelial space and plasma, respectively. In the penultimate stage of the 
coagulation cascade the protease thrombin converts fibrin from fibrinogen. Fibrin is then 




1.1.3.4 Innate/adaptive immunity 
 
Similarly to the blood coagulation cascade, at the onset of inflammation the endothelium 
orchestrates a series of molecular signalling events that facilitate the recruitment and 
migration of immune cells towards the injured or infected tissue. From a general 
perspective, the response of the endothelium during inflammation has been termed 
“activation” and it has been schematically divided into two phases (28). Phase I activation 
involves rapid signalling events that do not involve de novo transcription of inflammatory 
genes. During this phase ECs mediate the increase of blood pressure, the initial 
attachment of leukocytes and the opening of gaps in the monolayer. Central to these 
processes are the ligands of G protein-coupled receptors such as histamine and the 
signalling pathways mediated by intracellular Ca2+. Phase II activation involves the same 
processes as Phase I but the stimulation is predominantly provided by inflammatory 
cytokines, such as Tumour Necrosis Factor (TNF) and interleukin-1 (IL-1), which are 
mainly secreted by activated leukocytes. The signalling pathways promoted by these 
cytokines induce the expression of multiple genes whose function is to sustain and resolve 
the inflammation (28).  
Throughout the inflammatory response, the interaction between the ECs and leukocytes 
is coordinated by several molecular mechanisms. The traditional working model consists 
of a sequential three-step cascade: rolling, arrest and transmigration (29). Leukocyte 
rolling is mediated by single-chain transmembrane glycoproteins known as selectins, a 
family of cell adhesion molecules (CAM). L-selectin is expressed by leukocytes while P- 
and E-selectin are expressed by ECs. The interaction of these proteins with their ligands 
is responsible for the initial capture of leukocytes by ECs. The characteristic rolling is 
due to the low-affinity transitory nature of these bonds. The arrest of leukocytes is largely 
mediated by integrins, another family of transmembrane receptors, which are present on 
their surface. Integrins bind to immunoglobulin proteins expressed on activated ECs, such 
as VCAM-1 and ICAM-1. Several chemokines (e.g. CXC and CC families) modulate the 
binding affinity of integrins for their ligands and are essential for triggering leukocyte 
arrest. The final steps of leukocyte interaction involve transmigration through the 
endothelial layer (diapedesis), which can be achieved by both transcellular and 
paracellular routes (see section 1.1.3.1). In addition to the major component proteins of 
adherens and tight junctions, other proteins have been shown to mediate leukocyte 
migration, including PECAM1 (Platelet endothelial cell adhesion molecule), JAMs and 
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1.2 Epithelial Mesenchymal transition (EMT) 
 
 
1.2.1 Epithelial and Mesenchymal dichotomy 
 
“Epithelial” and “mesenchymal” refer to the two possible arrangements of cells in 
multicellular organisms. These arrangements are largely the result of the adhesive 
properties of individual cells. In an epithelium, cells develop complex cell-cell junctions 
and adhere firmly to each other (see section 1.1.3.1). As a result, epithelial cells form 
contiguous sheets characterised by two fundamental functional aspects: i) a barrier 
between “interior” and “exterior” biological compartments, ii) vectorial transport of 
molecules across this barrier (31). These properties emerge as a direct consequence of 
their membrane domain organization; besides the already mentioned cell-cell junctions, 
epithelial cells present an apical (the free surface facing the external space) and a basal 
domain (the point of contact with internal tissues) that together determine their defining 
characteristic: “apico-basal polarity” (32). Furthermore, this polarization involves other 
cellular elements such as the cytoskeleton and several cytoplasmic organelles (33).  
Mesenchymal cells are characterised by a contrasting organization; they do not display a 
compacted and regular arrangement as they lack strong cell-cell junctions. Rather than 
epithelial apico-basal polarity, mesenchymal cells present a “front-back” polarity that 
allows them to migrate (34).  
Overall, the definitions provided above describe a general organization of cells. Epithelial 
and mesenchymal can in fact be viewed as “cellular states” and these terms can 
encompass several types of differentiated cells. In light of these definitions, the ECs that 
cover blood vessels and the epithelial cells, rich in microvilli, that line the small intestine 
are both specialized types of epithelial tissues. On the other hand, fibroblasts, cells of the 
connective tissue that provide structural support to the surrounding tissues, are examples 




1.2.2 Interconversion of epithelial and mesenchymal phenotypes: the EMT 
 
In embryonic development, epithelial and mesenchymal cells are not fixed cell types that 
differentiate into the same kind of cell. Instead, they can dynamically change from one 
configuration to the other. This conversion is called epithelial-mesenchymal transition 
(EMT) (35). During development EMT is necessary for the formation of the three 
embryonic germ layers. As embryonic development starts with a single epithelial sheet, 
the epiblast, EMT allows cells to detach and migrate away from the parental tissue and 
subsequently, to form new layers. The mesoderm is considered the first mesenchymal 
tissue, or the primary mesenchyme, for it maintains a relatively stable mesenchymal 
phenotype compared to the other two germ layers, ectoderm and endoderm (36). 
Subsequently, the mesoderm will differentiate into different types of tissues (e.g. bone, 
muscle, circulatory system) through the inverse process of mesenchymal to epithelial 
transition (MET). In general, several cycles of EMT and MET are responsible for the 
formation of different organs and tissues during embryonic morphogenesis (37). Other 
examples of well characterised EMTs during embryogenesis are the formation of neural 
crest cells and the development of endocardial cushions in the heart (see section 1.3.1).  
Earlier studies into the mechanism of EMT recognized the interplay of both internal 
genetic programs and the environmental signals acting upon cells. One of the first 
molecular events found to play a central role in embryonic EMT was the modulation of 
E-Cadherin, the prototypic cell-cell adhesion protein whose protein family appeared early 
in the evolution of multicellular organisms (38, 39). Both ectopic expression and gene 





1.2.3 EMT in cancer 
 
The EMT attracted increasing attention from the research community when this process 
was first linked to diseases such as cancer and fibrosis. Elizabeth Hay, a pioneer of the 
field, was the first to prefigure the involvement of EMT in tumour biology. In a paper 
published in 1982, Greenburg and Hay demonstrated that both embryonic and adult 
epithelial tissues, when embedded in collagen gels, gave rise to mesenchymal cells that 
migrated away from the explants (41). These cells presented pseudopodia and filopodia 
and resembled normal mesenchymal cells in vivo in terms of morphology and 
ultrastructure. The authors noted that the EMT was induced only when explants were 
suspended within the gel, but not when they were placed on top of it. The authors also 
noted that mesenchymal cells formed in areas where the apical surface of the epithelium 
was in close contact with the collagen gel, thus highlighting the importance of the 
extracellular environment as a physical inducer of EMT. This study showed that even 
adult epithelial cells possess the intrinsic ability to undergo EMT and sparked interest to 
further understand the underlying molecular mechanisms and the possible involvement 
in diseases. 
 
Later in the 80s,  Jean Paul Thiery’s group showed that rat bladder carcinoma cell lines 
changed their epithelial arrangement to acquire a fibroblastic morphology when cultured 
in a specific medium (42), thus suggesting a link between EMT and cancer. Increased 
motility and invasiveness, as well as cytoskeletal rearrangements involving the 
expression of the intermediate filament vimentin, were some of the most prominent 
features that characterised these cancer cells. The factor responsible for the induction of 
EMT was later identified as FGF1 (acidic fibroblast growth factor). The role of growth 
factor signalling in the alteration of cell morphology had been suggested a few years 
earlier when the first epithelial “scattering factor” was discovered (later identified as 
hepatocyte growth factor, HGF (43)) (44). Since then, a growing list of growth factor 
ligands, such as insulin-like growth factor (IGF), epidermal growth factor (EGF) and 
transforming growth factor beta (TGFβ) has been shown to induce EMT in several cancer 
cell lines (45). 
Further influential insights into the mechanisms controlling the EMT in tumour 
progression came with studies that showed that the E-Cadherin gene could be 
transcriptionally downregulated in epithelial cells by the transcription factors Snail and 
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Twist (46-48). Snail, a zinc finger protein, and Twist, a basic-helix-loop-helix (bHLH) 
transcription factor, were originally identified in Drosophila as two essential genes for 




1.2.4 EMT in tissue fibrosis 
 
Another important step in the growth of EMT research was the link between EMT and 
fibrosis. In a series of papers published from 2002 onwards, Eric Neilson’s laboratory has 
advanced the hypothesis that EMT is responsible for converting epithelial cells of the 
kidney into fibroblasts during fibrosis. Fibroblasts of the connective tissue are a 
heterogeneous cell population that becomes activated in tissue fibrosis and secretes large 
amounts of collagens. In order to characterise unique markers of fibroblasts, Neilson’s 
lab initially isolated a gene that they called FSP1 (fibroblast-specific protein, also known 
as S100A4) which they showed to induce the acquisition of a fibroblastic phenotype when 
over-expressed in an epithelial cell line. FSP1 was also stained in vivo in tissue sections 
of mouse fibrotic kidneys (50). The occurrence of EMT in vivo was later confirmed in a 
mouse lineage-tracing model. FSP1+ fibroblasts accumulating in fibrotic kidneys were 
found to be derived from epithelial cells (51). This finding established the idea that EMT, 
in addition to development and cancer, was also a crucial process involved in chronic 
conditions of adult tissues, sparking much interest in this research field over the following 




1.3 Endothelial-mesenchymal transition (EndMT) 
 
 
1.3.1 Origin of the EndMT concept 
 
The first evidence of ECs transforming into mesenchymal cells was provided by 
Markwald et al. in 1977 (53). Their study aimed to investigate the cellular composition 
of specific areas of the developing vertebrate heart called cardiac cushions. These 
structures eventually form the atrioventricular and semilunar cardiac valves. During early 
embryogenesis, the heart develops as a single tube composed of two layers, the 
myocardium and the endocardium. Cardiac cushions in this primitive tube appear as 
swellings between the two layers and are composed of mesenchymal cells and 
extracellular matrix. Using histological, cytological and ultrastructural techniques in both 
chick and mouse embryos, Markwald et al. set out to investigate the origin of 
mesenchymal cells of the cardiac cushions. Serial heart sections showed that the first 
mesenchymal cells were in close contact with the endothelium, then progressively 
migrating towards the opposite myocardial layer. These cells were characterised by 
elongated structures, primitive intercellular contacts and were surrounded by matrix. 
Besides a migratory appearance, they were also characterised by proliferation and a 
secretory phenotype. At the ultrastructural level, the mesenchymal cells shared similar 
cytoplasm organization to ECs. From these observations Markwald et al. concluded that 
the mesenchymal cells of the endocardial cushions were derived from the endothelium. 
They proposed a model in which a small number of ECs detach from the parent 
endothelium to give rise to “seeded” mesenchymal cells, which in turn are able to 
proliferate and invade the extracellular space. The molecular mechanism underlying this 
process was unknown, but the authors speculated that the composition of the extracellular 
matrix, and specifically the active secretion of proteins such as hyaluronan and collagen, 
could have a determining role in guiding the migration and proliferation of mesenchymal 
cells. Markwald et al. coined the term “epithelial mesenchymal transformation” to 


















Figure 3: Original drawing of endocardial cushions development by Markwald et al. (53). 
The figure describes the sequential steps of ECs transforming into mesenchymal cells that 
populate the endocardial cushions. First, the myocardium secretes matrix components while some 
ECs detach from the endocardial layer and form a protrusion towards the matrix. Secondly, cells 
lose contact with the endothelium and acquire a mesenchymal phenotype characterised by 
increased proliferation, secretion and migration. Finally, the newly formed mesenchymal cells 




1.3.2 Literature review of EndMT 
 
 
1.3.2.1 EndMT literature 
 
During the following three decades after the seminal EndMT study by Roger Markwald 
and co-workers in the late 70s (53), most research on this topic focused on the 
mechanisms underlying this developmental process. In these studies, endocardial cushion 
explants cultured ex vivo were pivotal to dissect the signalling pathways involved in 
EndMT (see section 1.3.2.4). 
As shown in Figure 4, from 2007 onwards EndMT research has grown exponentially as 
this process was suggested to be involved in several pathologies. Using mouse lineage-
tracing models, the laboratory of Raghu Kalluri in Harvard demonstrated the occurrence 
of EndMT in adult tissues during disease for the first time. In three papers, which are the 
most highly cited papers in the field at the time of writing, Kalluri et al. report a direct 
contribution of EndMT in the pathogenesis of cardiac fibrosis, kidney fibrosis and cancer 
(54-56), indicating EndMT as a promising therapeutic target for these conditions. 
In the following subparagraphs, the relevant literature concerning EndMT will be 
reviewed in chronological order. Studies on cultured ECs will be first described as they 
provide the cellular basis used later to corroborate the experiments in vivo. Table 1 
summarizes these in vitro findings, including the cell types and parameters used to assess 



















Figure 4: Research on endothelial mesenchymal transition 1994-2014. The Web Of Science 
database was queried with different terms related to EndMT, e.g., “[endothelial mesenchymal] 
transition”, “transdifferentiation”, “transformation”, and the graph illustrating EndMT-related 
papers was generated by the on-line tool. 
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1.3.2.2 EndMT in cultured endothelial cells 
 
Initial studies dealing with the hypothesis that ECs possess the capacity to 
transdifferentiate into mesenchymal cells aimed to clarify the developmental relations 
between ECs and smooth muscle cells (SMCs) and its implications in vascular disorders, 
such as atherosclerosis. The main parameter used to assess the conversion of ECs was the 
expression of alpha-smooth muscle actin (αSMA, HUGO gene name ACTA2), an actin 
isoform which had been found to be specifically expressed in vascular smooth muscle 
cells (57). In 1992 Arciniegas et al. reported that bovine aortic ECs express αSMA when 
stimulated in vitro with the growth factor TGFβ (58). A higher percentage of αSMA-
positive cells was observed with increasing incubation time and this effect was reversible. 
They thus concluded that TGFβ could induce the differentiation of ECs into smooth 
muscle cells. Since TGFβ was known to be present in atherosclerotic lesions, the authors 
proposed the involvement of this cellular process in atherogenesis. In line with these 
findings, DeRuiter et al. (1997) analysed in vivo embryonic ECs of quail dorsal aorta 
through cell tracing techniques (59). They reported that ECs could migrate into the 
subendothelial space, giving rise to mesenchymal cells which lost an endothelial-specific 
marker and expressed αSMA. These findings added more evidence for the hypothesized 
interconversion between ECs and SMCs during development. Furthermore, since the 
study focused on fully differentiated ECs, they confirmed the hypothesis that the 
endothelium could potentially contribute to the disease of the vessel wall.  
Subsequently, Paranya et al. (2001) showed that clonal populations of mature ECs derived 
from ovine aortic valves could be induced to express αSMA with or without TGFβ (60). 
Moreover, cells expressing αSMA also showed increased capacity to migrate towards 
PDGFβ. The authors therefore concluded that mature ECs could reactivate the 
endothelial-mesenchymal transdifferentiation program previously observed in the 
development of endocardial cushions. Contrary to the previous in vitro findings, they 
reported that this effect was specific to valve endothelium since ECs  from other vascular 
sources (e.g. HDMECs (human dermal microvascular endothelial cells), HUVECs 
(human umbilical vein endothelial cells) or ECs derived from ovine peripheral veins) 
failed to express αSMA, even in the presence of TGFβ.   
Further data on the mesenchymal plasticity of ECs came from Frid MG et al. (2002). 
Through a cell sorting FACS approach, the authors found that a small population of cells 
within purified bovine aortic and pulmonary endothelium presented features of 
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mesenchymal cells. The percentage of cells amounted to 0.01-0.03 %. The authors 
showed that these cells not only expressed αSMA but, over time in culture, they also 
stained positive for other smooth-muscle-related markers, such as Sm22, Calponin and 
SM-myosin. The emergence of this phenotype was dependent on TGFβ but independent 
of cell proliferation. The authors were among the first to suggest that this phenomena 
could share common mechanisms with the epithelial-mesenchymal transition (EMT). 
They suggested a model in which ECs give rise to mesenchymal cells via EMT and 
subsequently differentiate into smooth-muscle cells.  
 
The first in vitro evidence that human ECs retain the ability to transdifferentiate to 
smooth-muscle cells was provided by Ishisaki et al. in 2003. They showed that HUVECs, 
when deprived of the growth factor FGF for several weeks, gave rise to enlarged cells 
expressing calponin and SM22. However, the expression of endothelial markers vWF and 
PECAM1 was not significantly changed. Furthermore, FGF-deprived HUVECs showed 
increased contractility in an in vitro assay compared to control cells. The authors also 
reported that activin-A signalling was involved in this phenotypic change.  
Further molecular details on the induction of mesenchymal features in ECs came from 
the study of Noseda et al. (2004). The investigators showed that the activation of Notch 
signalling was necessary to induce a mesenchymal transformation. Expression of the 
intracellular domain of Notch in different endothelial cell types (ovine ECs, human 
immortalized endothelial cells (HMECs), HUVECs and human aortic endothelial cells 
(HAECs)) led to an increased number of cells expressing αSMA. These effects were not 
dependent on TGFβ and the addition of TGFβ itself was not able to induce EndMT or 
αSMA expression. Besides inducing αSMA, Notch expression in HMEC also down-
regulated endothelial (VE-Cadherin, PECAM1, Tie1, Tie2 eNOS) and mesenchymal 
markers (fibronectin and PDGFR).  Moreover, the authors reported that Notch-expressing 




Author/Year Summary Phenotype analysed Cell type Ref. 
Arciniegas E. 
et al. 1992 
ECs differentiate 
into smooth 
muscle-like cells in 
the presence of  
TGFβ1 
 
αSMA upregulation by IF 
(immunofluorescence) and 
WB (Western blot). FVIII 






et al. 1997 
Embryonic ECs 
transdifferentiate 
in vivo into sub-
endothelial 
mesenchymal cells 
Colloidal gold EC tracing- 












Co-localization of GFP 
(green fluorescent protein) 
expression (precedent 
retroviral infection)  and 











to a mesenchymal 
phenotype 
Upregulation of αSMA by 




Frid M.G. et 
al. 2002 
ECs gives rise to 
smooth muscle 
cells via EndMT 
Decreased DiI-Ac-LDL 
uptake by FACS;IF staining 












Calponin expression by IF; 
calponin and SM22 mRNA 
upregulation by RT-PCR; 
increased contractility 
HUVECs (63) 







Cell morphology by bright-
field microscopy; 
downregulation of VE-
Cadherin, Tie1, Pecam1, 
eNOS and upregulation of 
αSMA, fibronectin, PDGFR 





























Upregulation of  calponin, 
SM-MHC and αSMA by WB, 
actin stress fibres formation 




Zeisberg M. et 
al. 2007 
Human ECs gives 
rice to fibroblast-
like cells via EndMT 





Col1A1 upregulation by IF; 
vimentin and fibronectin 






Medici D. et 
al. 2010 
ECs gives rise to 
multipotent stem-
like cells 
Cell morphology by bright-
field microscopy,; VE-
cadherin, Pecam1, vWF 
downregulation and FSP-1, 
αSMA, N-cadherin 
upregulation by WB; FSP1 
upregulation by FACS; Snail, 
Slug, ZEB-1, SIP-1, LEF-1 and 







Table 1: Summary of the main publications reporting EndMT-related phenotypes in 
cultured endothelial cells. The studies are listed in a chronological order with information 




1.3.2.3 EndMT is involved in different pathologies. 
 
The application of genetic recombination techniques in cell lineage-tracing studies 
offered an important opportunity to investigate the origin of different cell types in mouse 
disease models (68). In 2007, Zeisberg et al. put forward the hypothesis that fibroblasts 
accumulating in cardiac fibrosis were derived from ECs. This study followed their 
previous suggestion that in kidney tissue fibrosis, fibroblasts originated from the 
epithelium via an EMT (51) (see section 1.2.4). Zeisberg et al. used a transgenic mouse 
in which ECs were labelled through the Tie1 promoter, and stained mesenchymal cells 
for the fibroblast marker FSP1. They also used FSP1-GFP mice and Pecam1 staining as 
an alternative strategy. They thus determined that in fibrotic hearts the percentage of cells 
co-expressing mesenchymal and endothelial markers increased compared to normal 
hearts. They calculated that 27-35% of all fibroblasts accumulating in cardiac fibrosis 
were derived from ECs through an EndMT. In vitro experiments corroborated those 
findings, as human coronary ECs (HCEC) treated with TGFβ1 acquired a fibroblast-like 
morphology. Immunofluorescence staining of these cells showed a consistent EMT 
pattern: downregulation of endothelial markers (VE-Cadherin, PECAM1) and 
upregulation of mesenchymal proteins (FSP1, vimentin, pro-collagen I and αSMA). 
Overall, the study performed by Zeisberg et al. suggested for the first time that ECs could 
undergo an EndMT even in adult tissues, with important implications for cardiovascular 
disorders. Furthermore, the recapitulation in vitro of this phenomenon offered good 
opportunities to decipher the molecular mechanisms underlying the process.      
 
Using similar in vivo experimental strategies, the Kalluri group further extended the 
relevance of EndMT to other different pathological conditions, such as kidney fibrosis 
and cancer. Tie2-Cre reporter mice indicated that a substantial amount of FSP1-positive 
fibroblasts, which accumulate in kidney fibrosis and in tumours as cancer-associated 
fibroblasts (CAF), originated from ECs. The authors then proposed the EndMT process 
as a general feature of tissue remodelling during fibrosis, including the formation of a 
stromal component that facilitates tumour progression. 
In 2010, the Kalluri group in collaboration with Bjorn Olsen brought EndMT to a new 
dimension, showing that ECs could transform into multipotent stem-like cells. The 
authors determined that in fibrodysplasia ossificans progressiva (FOP), a disease in 
which soft tissues such as muscle or ligaments turn into bone, the ossified regions were 
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of an endothelial origin, thus implicating EndMT in the progression of the disease. 
Lineage tracing experiments with Tie2-Cre reporter mice indicated that chondrocytes and 
osteoblasts were in fact derived from ECs. Human ECs cultured in vitro retained this 
remarkable plasticity. In HUVECs and HCMECs both the inactivation of ALK2 (the 
disease-causing gene) and exogenous treatment with TGFβ2 or BMP4 induced a clear 
EMT pattern: endothelial markers shut down (VE-Cadherin. PECAM1, vWF) and 
mesenchymal genes switched on (FSP1, αSMA, N-Cadherin).  Furthermore, ALK2-
deficient HUVECs gave rise to mesenchymal cells which could further differentiate into 
chondrocytes, osteoblasts or adipocytes when cultured in specific media. These findings 
highlighted a remarkable and unexpected potential of EndMT; the process was now 
implicated not only in organ fibrosis and cancer, but also in bone fracture repair. 
Furthermore, the apparently easy way of turning ECs into different cell types promised 
valuable applications in tissue bioengineering (69).     
 
Following the general principles and experimental designs delineated by the Kalluri 
group, EndMT has been subsequently implicated in other pathologies. For instance, in a 
mouse model of lung fibrosis induced by the drug bleomycin, which recapitulates the 
disease idiopathic pulmonary fibrosis (IPF), fibroblasts that were activated in the lung 
interstitium were reported to be derived from capillary ECs (70). Moreover, using 
different vein graft models, EndMT was also found to generate cells of the neointima, a 
tissue remodelling process underlying several cardiovascular conditions (71). These 
studies highlighted a causal role for TGFβ and FGF signalling in triggering the EndMT 
in ECs both in vivo and in vitro.  
Finally, EndMT was also found to contribute to intestinal fibrosis, a condition that 
characterises inflammatory bowel diseases (IBD) (72). The authors reported that 




1.3.2.4 Molecular mechanisms of EndMT 
 
The first investigations into the molecular mechanisms of EndMT focused on the 
development of cardiac valves, a process in which endothelial transdifferentiation had 
been previously well characterised (see section 1.3.1). These studies used endocardial 
cushion explants cultured ex vivo as they proved to be informative tools to investigate the 
signalling pathways underlying the induction of EndMT (73). The general model of 
EndMT regulation emerging from these systems highlighted an interplay between the 
different tissues that form the primordial heart tube; inductive signalling factors are 
secreted from the myocardium and bind to specific receptors expressed by a subset of 
ECs, and the proteins of the extracellular matrix between the myocardium and 
endothelium actively participate in the progression of EndMT (74).   
Mouse knockout studies subsequently complemented the initial experiments on cardiac 
cushion development, leading to the identification of the main EndMT factors the 
underlying signalling pathways: TGFβ-BMP, Wnt/β-Catenin, Notch and ErbB (75). 
Among these, TGFβ signalling has received particular attention given its role in 
developmental EndMT and, potentially, EndMT-induced fibrosis (76, 77), 
TGFβ is a multifunctional cytokine that controls cell proliferation, differentiation and 
death depending on the cell type and cell environment. It is part of a large superfamily of 
factors that counts 33 members in mammals, including TGFβs, activin and inhibin, BMPs 
and Nodal (78). The common transduction pathway of these related factors consists of i) 
the binding to membrane receptors that have a cytoplasmic serine/threonine kinase 
domain, ii) the assembly of a receptor complex that phosphorylates proteins of the SMAD 
family, iii) the translocation of SMAD proteins in the nucleus where they bind DNA and 
regulate the transcription of target genes (Figure 5). Different combinations of receptor-
Smad proteins, together with cell type-specific factors, ensure the specificity of each 
TGFβ -related factor (79).  
Several in vitro and in vivo studies report that TGFβ ligands are the main inducers of 
EndMT in ECs. Among the three mammalian TGFβ isoforms (TGFβ1-3), only the knock-
out of TGFβ2 abolishes the formation of heart valves in mice (80). This is consistent with 
an earlier study showing different temporal requirements for TGFβ2 and TGFβ3, but only 
TGFβ2 being necessary for the induction of EndMT in endocardial cushions (81). TGFβ2 
has been shown to signal primarily through the type I receptor ALK5, which interacts 
with the type II TGFβ receptor and endoglin (82). Since most knockout mice for Smad 
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genes are embryonically lethal, little information exists regarding the intracellular 
mediators of EndMT in vivo. However, a recent study showed that the endocardial-
specific deletion of Smad4 blocked EndMT resulting in acellular cardiac cushions (83). 
The EMT key regulators Snail and Slug (see section 1.2.3) have also been shown to be 
necessary for EndMT during endocardial cushion development. A cooperation between 
Notch and TGFβ signalling pathways has been reported for the activation of these two 
transcription factors but conflicting findings are reported regarding their individual 
contribution (84, 85). In these studies, the function of Snail/Slug to downregulate the cell-
cell junction protein VE-Cadherin, as it was previously established for E-cadherin in 
EMT, has been demonstrated indirectly in immortalized endothelial cell lines.     
A few studies attempted to further characterise the EndMT molecular events in primary 
ECs culture in vitro. Kokudo et al. for instance used mouse ECs derived from embryonic 
stem cells (MESECs) and showed that Snail was responsible for TGFβ2-dependent 
downregulation of Claudin-5 and upregulation of mesenchymal/smooth muscle cell 
markers (86). Similarly, Medici et al. reported that Snail had a necessary role in the 
EndMT-related protein expression changes induced by TGFβ2, but its overexpression 
alone was not sufficient to induce the same phenotype. Furthermore, the TGFβ2 signal 
transduction mechanisms responsible for the activation of Snail were shown to comprise 
both SMAD-dependent and SMAD-independent signalling pathways (87). In SMAD-
dependent pathways, the type I receptor ALK5 is involved and the signal is propagated 
by SMAD2 and SMAD3 (88). SMAD-independent pathways include several intracellular 
kinases such as extra-cellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase 
(JNK), and p38 MAP kinase (89). The current model of the TGFβ signal transduction 









Figure 5: Currently proposed model for TGFβ signalling pathway in EndMT induction. 
TGFβ ligands bind to cell membrane receptors, determining the phosphorylation of Smad2 and 
Smad3 and their association with Smad4. The Smad complex translocates into the nucleus to 
activate the transcription of Snail, which in turn leads to the downregulation of endothelial 







1.4 Histone deacetylases (HDACs) 
 
The epigenetic regulation of chromatin has long been recognized to play an important 
role in EMT (90). Epigenetic modifications are crucial in the signalling cascades that 
drive differentiation and developmental processes, since they provide a rapid and 
reversible way to control gene expression, without changing the DNA sequence (91). 
Methylation of DNA and acetylation/methylation of histone proteins are the two major 
forms of epigenetic regulation that ultimately alter the chromatin structure, which in turn 
has a profound effect on gene function. 
Acetylation correlates with active gene transcription as the chromatin structure is relaxed 
and accessible to transcription factors and RNA polymerases. Conversely, the 
deacetylation of histone tails results in the compaction of chromatin which represses gene 
transcription, impeding the binding of the transcriptional machinery to gene promoters 
(92). The balance of these two counteracting mechanisms is finely regulated by two 







1.4.1 HDAC protein family 
 
The mammalian genome encodes 18 HDACs which are grouped into four classes 
according to their homology with yeast histone deacetylases (93). All members share a 
highly conserved deacetylase domain but differ in structure, subcellular localization and 
expression pattern, that results in different cellular functions (see Table 2). Class I 
members (similar to yeast Rpd3) include HDAC1, -2, -3 and -8, which are ubiquitously 
expressed in many human tissues and cell lines. They mainly localize to the nucleus and 
their lengths range from 400 to 500 amino acids. However, recent studies have revealed 
that both HDAC3 and HDAC8 can shuttle between the cytosol and the nucleus (94, 95). 
With the exception of HDAC8, whose function has been poorly characterised, Class I 
HDACs form large multi-subunit complexes that associate with transcription factors and 
other chromatin modifiers(96). In mammals, HDAC1 and -2, which display high 
structural similarity, can bind to each other forming the catalytic core of three different 
complexes: Sin3, nucleosome remodelling deacetylase (NuRD) and corepressor of RE1-
silencing transcription factor (CoREST). HDAC3 can form two different multi-protein 
complexes, nuclear receptor corepressor (N-CoR) and silencing mediator of retinoic acid 
and thyroid hormone receptors (SMRT). Since they are mainly found in such nuclear 
complexes, the deacetylation of histones to repress gene transcription is the predominant 
function of Class I HDACs. Furthermore, their association with several different proteins 
indicates the complex and tight regulation of their activity, which is highly pronounced 
in developmental processes that require a global modulation of transcriptional 
programmes. With the exception of HDAC8, knockout of Class I HDACs in mice have 
resulted in embryonic lethality (97). 
Class II HDACs are divided into two sub-classes. Class IIa members include HDAC4, -
5, -7, -9, while Class IIb comprises HDAC6 and -10. Members of these two subclasses 
(similar to yeast Hda1) mainly differ from Class I by their tissue-specific expression 
pattern and their considerably lower deacetylase activity. Other differences include their 
length (almost double of Class I HDACs) and their cellular localization, since Class II 
HDACs can shuttle between the nucleus and the cytoplasm. Class IIa HDACs differ from 
Class IIb members by the presence of binding sites for myocyte enhancer factor-2 (MEF2) 
and 14-3-3 proteins on the N-terminal extension of the protein. Their nuclear-cytoplasm 
shuttling and the occurrence of post-translational modifications such as phosphorylation, 
indicates their primary role as signal transducers, coupling external stimuli to 
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transcriptional regulation (98). Class IIb HDAC6 is the most abundant cytoplasmic 
deacetylase whose main function is to deacetylate cytoskeletal proteins, while little is 
known about the biological function of HDAC10, which presents a leucin-rich domain at 
the C-terminal,. Both Class I and Class II HDACs are sensitive to the inhibitor 
Trichostatin A (TSA). 
Class III HDACs are a group of proteins called Sirtuins (SIRT1-7). Although they possess 
a deacetylase domain, they diverge from classical HDACs   as their enzymatic activity 
requires the cofactor NAD+ (Nicotinamide adenine dinucleotide). This feature suggests 
their involvement in metabolic functions (99). 
HDAC11 is the most recently discovered and the only member of HDAC Class IV  (100). 
It shares the properties of both Class I and Class II HDACs but very few functions have 





Table 2: Members of the HDAC protein family 
Class Name length location Cellular functions 
I HDAC1 482aa nucleus 
Cell proliferation, blood cell 
development – forms large 
multiprotein nuclear repressive 
complexes 
 HDAC2 488aa nucleus 
Functions in complex with HDAC1 to 
exert overlapping processes 
 





Cell growth, apoptosis and 
differentiation. 




Regulation of centrosome and sister 
chromatid cohesion in mitosis 





Chondrocytes differentiation and 
formation of neuronal synapses 





Muscle cells differentiation and 
function 





Muscle cell differentiation, endothelial 
cell function, T lymphocytes apoptosis 





Myocyte differentiation, cardiac cells 
growth 




Cell migration, autophagy 





IV HDAC11 347aa Nucleus Cytokines expression in T cells 
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Endothelial cell (EC) proliferation is the initial step in the formation of new blood vessels 
(angiogenesis). Quiescent ECs in an intact vessel re-enter the cell cycle, requiring the 
reprogramming of gene transcription profiles. Cell cycle genes are up-regulated, while 
cell cycle-arrest genes are shut down. As one of the major chromatin structure regulators, 
HDACs are undoubtedly involved in this process. So far, the direct involvement of 
HDACs has been documented for HDAC1 and HDAC7. Tavar-Castillo L et al. reported 
that HDAC1 positively regulated hypoxia-inducible factor-1 alpha (HIF-1α), leading to 
VEGF production and angiogenesis (101). Lee D et al. recently reported that oscillatory 
shear stress up-regulated HDAC1/2/3 via the PI3K/Akt (RAC-alpha serine/threonine-
protein kinase) pathway, leading to the upregulation of cyclin A and downregulation of 
p21 (CIP1) and contributing to EC proliferation (102). These data suggest that HDAC1 
may promote EC proliferation through regulation of different signal pathways.  
HDAC7 is specifically expressed in ECs during embryogenesis, the disruption of which 
causes embryonic lethality at an early stage due to blood vessel rupture. HDAC7-null 
mouse embryos are characterised by enlarged but fragile blood vessels. These blood 
vessels have more ECs in numbers but lose cell-to-cell contact due to MMP10-mediated 
degradation of VE-cadherin (103). These observations indicate that HDAC7 maintains 
vascular integrity through preservation of EC adhesion and imply that HDAC7 may play 
a negative role in EC proliferation. Indeed, Wang et al. (104) reported that VEGF induced 
the phosphorylation of HDAC7 at three different sites via PKD kinase and the export of 
HDAC7 from the nuclei to release the repression of VEGF responsive genes. Margariti 
et al. (105) revealed that HDAC7 formed a complex with the signal transducer β-catenin, 
preventing its translocation to the nucleus that in turn keeps the ECs in a quiescent state. 
Stimulation with VEGF caused disruption of the complex and the translocation of β-
catenin into the nuclei, leading to cell proliferation. Considering the opposite effects of 
Class I HDACs (HDAC1) and Class II HDACs (HDAC7) on EC proliferation, the 






EC migration starts with the disruption of cell-to-cell contacts, which occurs through the 
breakdown of adherens junction and re-arrangement and polarization of the cytoskeleton. 
So far, the involvement of HDACs in EC migration is only documented for Class II 
HDACs. As described above, disruption of HDAC7 up-regulates MMP10, leading to 
breakdown of VE-cadherin, which suggests that HDAC7 may play an inhibitory role in 
EC migration.  However, Mottet et al. (106) reported that the silencing of HDAC7 through 
siRNA transfection inhibited EC tube formation and migration, partially due to the 
upregulation of platelet-derived growth factor-B (PDGF-B) and its receptor PDGFR-β, 
which suggests that HDAC7 may play a positive role in EC migration. In contrast to 
controversial reports into HDAC7 in EC migration, the roles of HDAC5, 6 and 9 seem to 
be concordant. HDAC5 is reported to suppress the expression of FGF2 and Slit2, which 
are required for sprout development (107). VEGF-induces the phosphorylation of 
HDAC5 by PKD (108), exports HDAC5 out of the nucleus and releases the suppression 
of pro-angiogenic gene expression, increasing tube formation and migration. HDAC6 is 
a well-established regulator of cytoskeletal dynamics (109). It has been reported that 
HDAC6 stimulates membrane ruffling and polarization, essential steps in cell motility, in 
an EB1 dependent manner (110). EB1 localizes to the growing ends of microtubules. 
Kaluza et al. (111) also reported that HDAC6 promotes EC migration through the 
deacetylation of cortactin. Inhibition of HDAC6 deacetylase activity severely impaired 
EC migration.  Similarly to HDAC6, HDAC9 also plays a positive role in EC migration 
through repression of the transcription of the anti-angiogenic micro-RNA cluster miR-
17-92 (112). Therefore, the balance between different members of Class II HDACs and 
the homeostasis between the cytoplasmic and nuclear localisation of single Class II 




1.4.2.3 Cell survival 
 
The balance between apoptosis and cell survival in ECs is critical in determining the 
function of blood vessels (113). Apoptotic signals contribute to release of anti-angiogenic 
factors leading to vessel quiescence and even vessel regression, whereas the maintenance 
of cell survival promotes the formation of new blood vessels. The switch towards pro or 
anti-angiogenic signalling pathways depends on the microenvironment in which ECs 
reside, such as the presence of growth factors, the adhesion to extracellular matrix and 
mechanical forces generated by blood flow. In this aspect, Class I HDACs seem to play a 
major role. For instance, Zeng et al.(114) revealed that HDAC1 deacetylates the Tumour 
suppressor protein p53 in response to laminar flow. The activation of the HDAC1-p53 
pathway arrested ECs in the G0/G1 phase, a critical cellular response that promotes vessel 
relaxation. Furthermore, Aurora et al.(115) showed that HDAC1 participates in an anti-
angiogenic pathway driven by NF-κB. When ECs are stimulated by anti-angiogenic 
molecules, NF-κB increases the expression of HDAC1, which in turn decreases histone 
acetylation around the promoter region of the prosurvival protein cFLIP (CASP8 and 
FADD-like apoptosis regulator), leading to transcriptional suppression. Another key 
mediator of EC survival is HDAC3. HDAC3 acts as a prosurvival molecule to maintain 
the integrity of blood vessels through the activation of Akt1, one of the best known anti-
apoptotic kinases (116). HDAC3 expression was shown to be significantly increased in 
vessel areas subjected to turbulent blood flow, indicating that this histone deacetylase can 
“sense” the physical forces acting on the vasculature and induce a protective cellular 




1.4.2.4 Cell differentiation 
 
Whether or not endothelial differentiation from stem/progenitor cells contributes to the 
formation of blood vessels is still a debated topic. Circulating endothelial progenitor cells 
(EPCs) in peripheral blood were found to differentiate into ECs in vivo and in vitro, 
providing an additional differentiation route for angiogenesis (117). However, conflicting 
result have been reported so far, and the identity and function of EPCs remains 
controversial (118). Nonetheless, the differentiation of pluripotent stem cells into ECs is 
an area of investigation with great therapeutic potential. 
The epigenetic control of lineage-specific gene programmes has a primary role in stem 
cell biology (119).One of the first demonstrations of the role of HDACs in endothelial 
differentiation was provided through  investigation into the effect of HDAC inhibitors. 
Impairment of deacetylase activity blocks the differentiation of adult progenitor cells into 
ECs and the molecular mechanism of this effect was found to be mediated through  
reduced expression of the homeobox transcription factor Hox-A9, which in turn regulates 
the expression of endothelial-specific markers such as eNOS, VEGF-R2 and VE-
Cadherin (120). HDAC-dependent Hox-A9 activity was also found to be relevant in vivo, 
as it mediates the formation of EPCs and postnatal neovascularisation in ischemic tissues 
in mice.  
Further details of the involvement of HDACs in endothelial lineage commitment were 
reported by Spallotta et al.(121). The investigators showed that Class II HDACs, HDAC4 
and HDAC7 in particular, are specifically activated in embryonic stem cells (ESCs) 
exposed to nitric oxide (NO). As a result, global deacetylation of H3 histones and 
activation of mesoderm-specific genes were observed. NO-induced ESCs display 
promising therapeutic potential as they contribute to the regeneration of vascular and 
muscular structures in a mouse hindlimb ischemia model.  
In addition to its role in EC survival, HDAC3 is reported to be involved in EC 
differentiation. Laminar shear stress has been demonstrated to be an important stimulus 
that enhances embryonic stem cell or progenitor cell differentiation to an EC lineage. 
During this process, Zeng et al. found that laminar flow stabilized HDAC3 protein via the 
VEGF receptor-PI3K–Akt pathway in a ligand independent manner, which in turn 
deacetylated p53 and activated p21, contributing to EC differentiation. A similar 




1.4.2.5 Mural cell recruitment 
 
The final stages of the vasculature formation require the recruitment of mural cells 
(pericytes and smooth muscles cells (SMCs)) and the generation of the extracellular 
matrix (ECM). This maturation process confers structural and functional support to the 
newly formed blood vessels (11). SMCs, pericytes and ECM components may 
furthermore represent an important but largely unexplored source of molecular signals 
that regulate ECs under physiological and pathological conditions. The contribution of 
HDACs to the differentiation and function of SMCs provides insights into the molecular 
characterization of the current anti-angiogenic therapies. The presence of transcription 
factor MEF2 binding sites at the N-terminal of Class II HDACs (HDAC4-5-7-9) initially 
pointed to their crucial role in myogenesis during embryonic development (123). Further 
study uncovered a more complex situation in which HDACs can also regulate smooth 
muscle differentiation (124). HDAC5 was found to participate in the dual function of the 
transcription factor Myocardin, which induces the activation of the smooth muscle gene 
programme, and represses the transcription of skeletal muscle genes (125).  
The role of HDACs is not confined to development but it is also related to the function of 
differentiated SMCs. Waltregny et al. (126) showed that HDAC8 is associated with the 
cytoskeleton of SMCs and could regulate their contractility. In another report, van der 
Veer et al. (127) demonstrated that NAD+ dependent deacetylase activity is necessary to 
induce phenotypic change to a contractile state, thus suggesting the involvement of 
sirtuins in blood vessel maturation.  
Recently, the role of HDACs in mural cells in the context of angiogenesis has been 
addressed directly in human pericytes. Karen et al. (128) showed that different HDAC 
inhibitors impair pericyte migration, proliferation, and their differentiation towards 
collagen I-producing fibroblasts, indicating that HDACs keep the pericytes in a 
proangiogenic phenotype. This effect is accompanied by the expression of different 
angiogenic genes involved in the stabilization and maturation of the remodelling vessels. 
As noted by the investigators, these results may therefore offer additional ways to explain 
at cellular level how HDAC inhibitors effectively reduce Tumour angiogenesis in vivo. A 














p53, NF-κB (114), (115) 
HDAC3 Cell survival, EC 
differentiation 
under shear stress 
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HDAC4 Hypoxia gene 
programme 
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HDAC8 SMCs contractility alpha-SMA (126) 





1.5 Project Background  
 
The present PhD research project is based on previous findings of the host laboratory 
regarding the functional characterization of new HDAC3 isoforms. Below are 
summarised the most relevant results that frame the background of this thesis. 
 
 
1.5.1 HDAC3 gene gives rise to multiple splicing variants 
 
HDAC3 has been found to undergo extensive RNA processing during stem cell 
differentiation and mouse embryonic development. As shown in Figure 6 A, the RT-PCR 
on total RNA from mouse embryos and new born mice, revealed multiple transcripts of 
different sizes. These transcripts were isolated and sequenced, leading to the identification 
of four isoforms named HDAC3α, β, γ and δ. The exon-intron structure of these isoforms 
is illustrated in Figure 6 B. Compared to the full-length cDNA of HDAC3, an extensive 
sequence rearrangement occurs: intron 12 is kept as an additional exon in HDAC3α, β 
and δ, while in all isoforms several exons in the 5’ region are spliced out. A 
recombination-like event seems to occur between exons 3 and 9 in HDAC3α and between 
exons 3 and 10 in HDAC3β.  
To verify that these sequences were correctly translated into proteins, cDNAs 
corresponding to the four isoforms were cloned in flag-tag expression vectors, which were 
in turn transfected in 293 cells. As shown in Figure 6 C, Western blot with anti-flag 
antibodies revealed protein bands whose sizes corresponded to the ones predicted from 
cDNA sequences. To determine whether the protein expression of the splicing variants 
occurred in a physiologic cellular context, the GFP coding sequence was inserted in the 
intron 12 within the open reading frame of HDAC3α and β in a mouse embryonic stem 
cell (ESC) line. As shown in Figure 6 D, when ESCs were induced to differentiate, some 
cells expressed GFP. Thus, these results demonstrate that at least two splicing variants, 






Figure 6: Characterization of HDAC3 splicing variants. A) RT-PCR analysis of HDAC3 
mRNA expression performed on RNA samples extracted from mouse embryos at different stages 
and from newborn mice. β-actin expression represents the internal control. B) Schematic 
illustration of the exon-intron structure of the four HDAC3 isoforms. C) The expression of 
individual isoforms were analysed in 293 cells by Western blot with antibodies against Flag-tag. 
D) Schematic representation of GFP inserted into HDAC3 intron 12 within the open reading frame 
of HDACα and β isoforms (upper panel). Bottom panel: GFP expression in HDAC3 α/β-GFP 




1.5.2 HDAC3α overexpression induces the endothelial-mesenchymal transition in 
HAECs 
 
The function of HDAC3α was investigated in primary ECs through an adenoviral-
mediated gene overexpression system. HAECs were infected with Ad-HDAC3α or Ad-
null viruses in the presence of serum-free medium. 72 hours after infection, ECs lost the 
characteristic round shape and acquired an elongated fibroblast-like morphology (Figure 
7 A). An immunofluorescence staining was then performed to check whether this 
morphological change was accompanied by altered expression of EndMT markers. Cells 
treated with Ad-Null virus expressed high level of the endothelial-specific junction 
protein VE-Cadherin (Figure 7 A, bottom panels), while in the presence of Ad-HDAC3α 
its expression was significantly reduced. Furthermore, HDAC3α-overexpressing cells 
showed positive expression of the mesenchymal marker αSMA around the nucleus, which 
is absent in Ad-null control cells.  
 The induction of EndMT-associated markers was subsequently analysed through Western 
blot in HAECs infected with different concentrations of Ad-HDAC3α viruses (Figure 7 
B). HDAC3α downregulated the endothelial marker Pecam1 and induced the expression 
of mesenchymal proteins N-Cadherin, αSMA and Snail2 in a dose-dependent manner. 
Taken together, these results indicate that HDAC3α overexpression induces 
morphological and biochemical changes consistent with the endothelial-mesenchymal 







Figure 7: HDAC3α overexpression induces EndMT in HAECs. Upper panel: HAECs infected 
with Ad-Null or Ad-HDAC3α viruses in the presence of serum-free medium. Bright field images 
were taken 72 hours post infection (top panels). Immunofluorescence staining performed with 
antibody against VE-Cadherin and αSMA (bottom panels). Bottom panel: Western blot analysis 





Chapter II – Materials and Methods 
 
 
2.1 In vivo methods 
 
2.1.1 Minimal invasive transverse aortic constriction (TAC) in mice 
 
Surgical TAC procedures were performed by Dr. Xuebin Dong (Department of 
Cardiology, King’s College London) as described elsewhere (131). Male C57/BL6 mice 
weighing 20–30 g were used in the experiments. Echocardiography was performed on the 
day of harvesting to validate myocardial hypertrophy. After collection, hearts were 




2.1.2 Protein extraction from heart tissue 
 
Frozen heart tissues were placed in Matrix D tubes (MP Biomedicals) in the presence of 
400 μl of lysis buffer. Tissues were mechanically disrupted using the FastPrep machine. 
Tissue lysates were then transferred in 1.5 ml sterile eppendorf tubes, sonicated with the 
Branson Sonifier 150 at the lowest setting for 10seconds at 4ºC and incubated for a further 
30minutes on ice. The lysates were then centrifuged at 16000xg for 15minutes at 4ºC. 
The supernatants were transferred into new micro-centrifuge tubes and protein levels 
were measured using the Biorad Protein Assay on the Biorad Spectrophotometer 3000. 
 
 
2.1.3 RNA extraction from heart tissue 
 
Frozen heart tissue was placed in Matrix D tubes (MP Biomedicals) in the presence of 
500μl of RNA lysis buffer from miRVANA kit (Ambion). Tissues were mechanically 
disrupted using the FastPrep machine. RNA from tissue lysates was extracted with acid-
phenol:chloroform method following the miRVANA kit protocol. RNA was eluted in 25μl 
of DEPC (diethyl dicarbonate)-treated water and the concentration was measured using a 





2.1.4 Picrosirius red staining of heart paraffin sections 
 
Paraffin heart sections (10μm) were de-waxed in xylene and ethanol and rinsed in water. 
Sections were then immersed in 0.2% phosphomolybdic acid (Fluka), rinsed in water and 
immersed in 0.1% Picrosirius Red (Direct Red 80, Fluka) for 2 hours. After 2 washes in 
acidified water, sections were dehydrated with increasing concentration of ethanol, 
cleared in xylene and finally mounted with DPX (Di-N-Butyle Phthalate in Xylene) 
mounting medium (Sigma).   
 
 
2.1.5 Immunofluorescence staining of heart frozen sections 
 
10μm heart sections were prepared from frozen mouse hearts with the cryostat and stored 
at -20°C. Before immunostaining, sections were dried at RT for 30 minutes and then fixed 
in methanol for 15 minutes. After one wash in PBS (Phosphate-Buffered Saline) for 5 
minutes, sections were permeabilized with 0.1% Triton X-100 in PBS at RT for 15 
minutes and washed three times with PBS for 5 minutes. Blocking solution of secondary 
antibody normal host serum diluted 1:20 in PBS was then applied for 1 hour at RT. 
Sections were then incubated with primary antibody (anti-HDAC3α 1:50 in blocking 
solution, anti-CD31 (BD bioscience) 1:100 in blocking solution) at RT for 1 hour or at 
4°C overnight. After washing three times with PBS, secondary antibodies (Alexa Fluor -
Invitrogen) were diluted 1:1000 in blocking solution and applied to the sections for 45 
minutes. Samples were then counterstained with DAPI (4',6-Diamidino-2-Phenylindole, 
Dihydrochloride) at RT for 5 minutes, washed three times with PBS and mounted with 




2.2 Cell culture 
 
2.2.1 Cell culture of human aortic endothelial cells 
 
Postnatal HAECs were purchased from Sigma and cultured on gelatin-coated flasks 
(0.4mg/ml) in M199 medium supplemented with 1ng/ml β-endothelial cell growth factor, 
3μg/ml Endothelial Cell Growth Supplement from bovine neural tissue, 10u/ml heparin, 
1.25μg/ml thymidine, 10% foetal bovine serum, 100u/ml penicillin and streptomycin in 
a humidified incubator supplemented with 5% CO2. Cells were passaged every three days 
at a ratio of 1:3. Cells were used up to passage 8. Cell supplements and culture medium 
were purchased from Sigma and Gibco, respectively. 
 
 
2.2.2 Cell culture of HUVECs 
 
Pooled HUVECs were purchased from Lonza and used between passage 3 and 8. 
HUVECs were routinely cultured on gelatin-coated flasks in EGM2 medium with Bullet 
Kit (2% FBS + different growth factors) in a humidified incubator supplemented with 5% 
CO2. 2% stock solution of gelatin was purchased from Sigma and diluted to 0.2% for 
coating. Cells were split every 2/3 days and the medium changed every other day.  
 
 
2.2.3 Cell culture of Adventitia Progenitor Cells (APCs) 
 
APCs were provided by the laboratory of Professor Qingbo Xu (132). APCs were cultured 
on 2% gelatin-coated flasks in complete stem cell medium (American Type Culture 
Collection, Rockville, Massachusetts, USA) containing 10% FBS, leukemia inhibitory 









Human Recombinant TGFβ2, TNF and IL1β were purchased from Prepotech and diluted 
in milli-Q water following the manufacturer’s instructions.  All factors were used at a 
final concentration of 10 ng/ml. 
 
 
2.2.5 Cell freezing 
 
For long-term storage, cells were resuspended with the following solution: 50% cell 
culture medium, 40% FBS, 10% DMSO. After resuspension, cell solutions were 
transferred into 2.0 ml cryovials (Corning), put immediately on ice and stored in liquid 
nitrogen.    
 
 
2.2.6 Chemical inhibitors 
 
Chemical inhibitors used in cell culture experiments are listed in Table 4below: 
 
Table 4: Chemical inhibitors used in cell culture experiments 
Inhibitor Company Target Concentration 
LY294002 Sigma PI3K/Akt 10µM 
PD98059 Sigma MAP kinase 10µM 
SB202190 Sigma p38 10µM 
SP60005 Sigma JNK 10µM 
Y27632 Sigma ROCK1 5 µM 
ML-7 Sigma MLCK 10µM 
Cycloheximide Sigma 60S ribosome subunit 10 µg/ml 
Actinomycin-D Sigma GpC sites of DNA 1 µg/ml 
C3 Transferase Cytoskeleton, Inc. RhoA, B, C 1 µg/ml 
IKK Inhibitor II Merck Millipore 
IKK (inhibitor of nuclear 





2.2.7 Other cell culture reagents 
 
Calcium and magnesium-free PBS was purchased from Sigma or Gibco and 
supplemented with penicillin-streptomycin (LifeTechnologies). Cell splitting was 
performed using Trypsin-EDTA (phenol red) purchased from LifeTechnologies.  
 
 
2.3 Gene expression analysis 
 
2.3.1 RNA Extraction from cells 
 
RNA extraction was performed using the RNeasy Mini Kit following the manufacturer’s 
protocol. Reactions were carried out at room temperature with a centrifugal force of 
10,000xg. To elute the RNA, RNeasy columns were transferred into clean 1.5 ml 
microcentrifuge collection tubes and 30 μl of RNase-free water was added to the RNeasy 
column membrane, followed by 1 minute spinning. The RNA concentration was 
measured using a NanoDrop1000 spectophotometer (ThermoScientific). 
 
 
2.3.2 Reverse transcription of RNA 
 
Reverse transcription was performed using the Improm-II Reverse transcription system 
(Promega) in a 20μl reaction as outlined in Table 5 below. Mix A was added to 1.0μg/10μl 
RNA and heated at 70°C for 5 minutes then chilled on ice to allow denaturation of RNA. 
Mix B was then added and the following programme was carried out: 22°C for 5 minutes; 
42°C for 1hour 30minutes; 70°C for 15minutes. cDNAs were then diluted in 80μl of 













Volume (μl) Final Concentration 
 
Mix A 
    
Improm II 5X reaction buffer 4 1x 
Random Primer 0.1 0.5μg 
25mM MgCl2 2.4 3mM 
25mM dNTP 0.4 0.5mM 
DEPC treated water 
 
to 7μl   
 
Mix B 
    
2500u Rnasin ribonuclease inhibitor 0.5 20u 
Improm II RT 1 1u 
DEPC treated water 1.5   
Total 
 





2.3.3 Quantitative real time polymerase chain reaction (qPCR) 
 
Relative gene expression was analysed by qPCR using the Eppendorf Mastercycler® ep 
realplex. For each sample, 15ng of cDNA was combined with 10μl of SYBR Green 
(Qiagen, Cat. No. 204057) and 0.75μM of forward + reverse primer mix for the target 
gene. The final volume was adjusted to 20μl with DEPC water and the samples were 
loaded on 96 well plates (Eppendorf twintec real-time PCR plates). The qPCR conditions 
were as follows: 5min at 95oC; 95oC for 15 seconds and 60oC for 30 seconds for 40 cycles; 
10 minutes of 95oC. For each sample, the qPCR reaction was performed in duplicate 
Threshold cycle (Ct) values of individual genes were then normalised against endogenous 
housekeeping genes (18s, GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) or 
RPL13A). Gene expression levels were calculated using the ΔΔCt method. The primers 
used for qPCR were designed using the on-line tool PrimerBLAST of NCBI 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) setting the following criteria: PCR 
product length of 120-180 bp, primer size 18-22, GC content of 40-60%. Other 
parameters were set automatically by the software. Alternatively, some primers were 
selected consulting the on-line database PrimerBank 
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(http://pga.mgh.harvard.edu/primerbank/). The complete lists of mouse and human 






Table 6: List of mouse primers used for qPCR analysis 
Primer Sequence (5'->3') 
VE-Cadherin Forward AGAAGAAACCGCTGATCGGC 
VE-Cadherin Reverse CACTGGTCTTGCGGATGGAG 
eNOS Forward ACCCTCCGCCATCCACAGAACC 
eNOS Reverse ACATGGGGGTAGCCGGGGGT 
αSMA Forward AGTGGAGAAGCCCAGCCAGTCG 
αSMA Reverse CCATTGTCGCACACCAGGGC 
FSP1 Forward (S100A4) AGACCCTTGGAGGAGGCCCTG 
FSP1 Reverse (S100A4) GGAAGCTAGGCAGCTCCCTGGT 
Collagen I alpha I Forward TGATGG CCAACCTGGTGCGA 
Collagen I alpha I Reverse ACCAACGTTACCAATGGGGCCG 
HDAC3α Forward AGCATTCGAGGACATGGGGAAT 
HDAC3α Reverse TGGCATCATGAAGTGGATCTTACC 
GAPDH Forward ACGGCCGCATCTTCTTGTGC 





Table 7: List of human primers used for qPCR analysis 
Primer Sequence (5'->3') 
TGFβ 1 Forward ACCCTCCGCCATCCACAGAACC 
TGFβ 1 Reverse ACGGCCGCATCTTCTTGTGC 
TGFβ 2 Forward AGACCCTTGGAGGAGGCCCTG 
TGFβ 2 Reverse TGGCATCATGAAGTGGATCTTACC 
TGFβ 3 Forward CATCATAGAACTCATTGGGTG 
TGFβ 3 Reverse ATTGTCGCACACCAGGGCTG 
ADAMTS1 Forward GGTGACTGGACACAAATCGC 
ADAMTS1 Reverse AAAGCGGAGACCGAAGACGA 
18s Forward GGTGACTGGACACAAATCGC 
18s Reverse ATACATGCCGACGGGCGCTG 
HDAC3 Forward CATCTCTGCTGGTAGAAGAGG 
HDAC3 Reverse CATCATAGAACTCATTGGGTG 
PECAM1 Forward GACATGGCAACAAGGCTGTG 
PECAM1 Reverse AGATTCCAGTTCGGGCTTGG 
VE-Cadherin Forward TTGGAACCAGATGCACATTGAT 
VE-Cadherin Reverse TCTTGCGACTCACGCTTGAC 
eNOS Forward TGATGGCGAAGCGAGTGAAG 
eNOS Reverse ACTCATCCATACACAGGACCC 
S100A4 (FSP1) Forward TCTTGGTTTGATCCTGACTGCT 
S100A4 (FSP1) Reverse ACTTGTCACCCTCTTTGCCC 
N-Cadherin Forward TCAGGCGTCTGTAGAGGCTT 
N-Cadherin Reverse ATGCACATCCTTCGATAAGACTG 
ACTA2 (αSMA) Forward TGGCTGGCCGAGATCTCACT 
ACTA2 (αSMA) Reverse TGCGGCAGTGGCCATCTCAT 
TAGLN (SM22) Forward CCGTGGAGATCCCAACTGG 
TAGLN (SM22) Reverse CCATCTGAAGGCCAATGACAT 
PDGFβ Forward CTCGATCCGCTCCTTTGATGA 
PDGFβ Reverse CGTTGGTGCGGTCTATGAG 
RND1 Forward GATGTAAGCTCGTTCTGGTCG 
RND1 Reverse AGCAATCCTTCGCTAACACTTG 
DLL4 Forward GTCTCCACGCCGGTATTGG 
DLL4 Reverse CAGGTGAAATTGAAGGGCAGT 
JAG1 Forward GTCCATGCAGAACGTGAACG 
JAG1 Reverse GCGGGACTGATACTCCTTGA 
Hey1 Forward GTTCGGCTCTAGGTTCCATGT 
Hey1 Reverse CGTCGGCGCTTCTCAATTATTC 
COL1A1 F TAACCCCCTCCCCAGCCACAAA 
COLA1 R TGGTGGGATGTCTTCGTCTTGGC 
COL1A2 Forward GAGCGGTAACAAGGGTGAGC 
COL1A2 REV CTTCCCCATTAGGGCCTCTC 
Tenascin-C Forward TCCCAGTGTTCGGTGGATCT 
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Tenascin-C Reverse TTGATGCGATGTGTGAAGACA 
Elastin Forward GCAGGAGTTAAGCCCAAGG 
Elastin Reverse TGTAGGGCAGTCCATAGCCA 
COL22A1 Forward TCCGACTTCAATGCCATCGAC 
COL22A1 Reverse TACACGAACGCTAGGACAGAG 
COL16A1 Forward CCACCAGAAGACGTGGTATCT 
COL16A1 Reverse CAGGACACAAAGTCGCCATC 
COL3A1 Forward GGAGCTGGCTACTTCTCGC 
COL3A1 Reverse GGGAACATCCTCCTTCAACAG 
COL4A3 GGATTGCCAGGATTTTCTGGT 
COL4A3 TGGTACACCGACAAGTCCGTA 
MMP1 Forward AAAATTACACGCCAGATTTGCC 
MMP1 Reverse GGTGTGACATTACTCCAGAGTTG 
LOX (Lysyl oxidase) Forward GCCGACCAAGATATTCCTGGG 
LOX Reverse GCAGGTCATAGTGGCTAAACTC 
RPL13A Forward CATAGGAAGCTGGGAGCAAG 





2.4 Protein expression analysis 
 
 
2.4.1 Protein collection 
 
Cell pellets were resuspended in 50μl RIPA (Radio-Immunoprecipitation Assay) buffer 
(Sigma) and incubated on ice for 15 minutes. The lysates were then sonicated with the 
Branson Sonifier 150 at the lowest setting for 10 seconds at 4ºC and kept 30 minutes on 
ice. Lysates were then centrifuged at 16000xg for 15 minutes at 4ºC. The supernatants 
were transferred to new micro-centrifuge tubes and protein concentrations were measured 
using the Biorad Protein Assay on the Biorad Spectrophotometer 3000. 
 
 
2.4.2 Western blot 
 
50μg of total protein were loaded in SDS buffer and boiled for 5 minutes before loading 
onto a NuPage, 4-12% gel (Invitrogen). The samples were run at 160V for about 80 
minutes in an XCell SureLock® Mini-Cell system from Invitrogen and transferred to a 
PVDF membrane (Amersham, hybond-P) at 25V for 1hour and 30minutes using an XCell 
II™ Blot Module (Invitrogen). Membranes were then blocked with 5% milk in PBS-
Tween 0.1% (PBS-T). The antibodies against HDAC3α and β were developed by 
Genescript in rabbit with peptide PQGDTILTSPQNDL and diluted 1:100 in 5% milk 
PBS-T. The complete list of antibodies used and relative concentrations is shown in Table 
8). Membranes were incubated with primary antibodies on a rotator either overnight at 
4ºC or at room temperature for minimum 2 hours minimum. Secondary HRP-conjugated 
antibodies (Dako) were diluted in 5% milk PBS-T (1:3000) and incubated for 45 minutes. 
Membranes were then treated with ECL detection reagents (Amersham) and exposed on 
films (Amersham, Kodak) using the Compact X4 instrument (Xograph Imaging System).  
Alternatively, membranes were incubated with dye-conjugated IRDye® secondary 
antibodies (LI-COR) diluted 1:15000 in 5% milk/PBS-T. Blots were then scanned using 









Table 8: Primary antibodies used in Western Blot analyses 
Antibody Company - code Concentration 




1:100 in 5% milk PBS-T 
Rabbit anti-HDAC3 Sigma (H3034) 1:100 in 5% milk PBS-T 
Mouse anti-αSMA Sigma (A5228) 1:100 in 5% milk PBS-T 
Mouse anti-FLAG Sigma (F3165) 1:100 in 5% milk PBS-T 
Rabbit anti-pSmad2 Sigma (SAB4300251) 1:100 in TBS-T 
Rabbit anti-TGFβ1 Abcam (ab9758) 1:100 in 5% milk PBS-T 
Goat anti-TGFβ2 Abcam (ab10850) 1:100 in 5% milk PBS-T 
Rabbit anti-Collagen IV Abcam (ab19808) 1:100 in 5% milk PBS-T 
Rabbit anti-VE-Cadherin Abcam (ab33168) 1:100 in 5% milk PBS-T 
Rabbit anti-IκBα Cell Signaling (4812) 1:1000 in 5% milk TBS-T 
Rabbit anti-pSmad2 
(Ser 465/467) 
Cell Signaling (3108) 1:1000 in 5% BSA TBS-T 
Mouse anti-Smad2 Cell Signaling (3103) 1:1000 in 5% milk TBS-T 
Rabbit anti-pCofilin (Ser3) Cell Signaling (3311) 1:1000 in 5% milk TBS-T 
Rabbit anti-Cofilin Cell Signaling (3318) 1:1000 in 5% milk TBS-T 
Mouse anti-NOS3 (eNOS) 
Santa Cruz Biotechnology 
(sc-376751) 
1:100 in 5% milk PBS-T 
Rabbit anti-Jagged1 
Santa Cruz Biotechnology 
(sc-11376) 





2.5 Gene overexpression/inhibition 
 
 
2.5.1 Adenoviral-HDAC3 gene transfer 
 
The Adenoviral-Flag-HDAC3α (Ad-HDAC3α) viruses were created from pShuttle2-
Flag-HDAC3α plasmid with the Adeno-XTM expression system (PT3414–1; Clontech). 
Viruses were produced, amplified in 293 cells, and titered (end point dilution assay) 
according to the protocol provided. For EndMT induction, HAECs were incubated with 
Ad-null or Ad- HDAC3α at 10 multiplicity of infection (MOI) for 6 hours. After removal 
of virus solutions, cells were cultured in human endothelial serum free medium (SFM, 
Invitrogen) for 48/72 hours and harvested.  
 
 
2.5.2 siRNA treatment 
 
SMARTpool siRNAs for JAG1, RND1 and non-targeting were purchased from 
Dharmacon and used at a final concentration of 20 nM in complete medium. Before 
transfection, siRNAs were complexed with Lipofectamin in opti-MEM medium (both 
from LifeTechnologies). In experiments with concomitant cytokine treatment, siRNA 





















2.6 Immunofluorescence analysis 
 
 
2.6.1 Immunofluorescence staining of HUVECs 
 
HUVECs were plated on Millicell EZ Slides (glass chamber slides) from Millipore coated 
with a solution of 1μg/μl of fibronectin (Sigma). Cells were washed three times with PBS 
containing NaCl and MgCl2 and then fixed in 3.8% PFA for 10 minutes. Subsequently, 
cells were permeabilized with 0.2 % Triton X-100 for 5 minutes, washed and blocked 
with 2% BSA in PBS for a minimum of 1 hour or left in PBS+ Sodium azide for long-
term storage. Alexa Fluor® 594 Phalloidin for Actin staining was purchased from 
Invitrogen and used 1/40 in 2% BSA PBS-T. Polyclonal Anti-VE Cadherin antibody 
(ab33168) was purchased from Abcam and used 1:100 in PBS-2% BSA. After primary 
antibody incubation, cell were washed 3 times with PBS-T and incubated with dye-
conjugated secondary antibodies (Alexa Fluor, Invitrogen) for 45 minutes at room 
temperature. Cells were then counterstained with DAPI (Sigma) at RT for 5 minutes and 
mounted with a fluorescent mounting medium (Dako). Immunofluorescence images were 
acquired through the Volocity software (PerkinElmer) using an Olympus IX81 inverted 




2.6.2 Immunofluorescence staining of HAECs. 
 
HAECs were washed twice in PBS and then fixed in methanol for 15 minutes. After 3 
washes in PBS for 5 minutes, cells were permeabilized with 0.1% Triton X-100 in PBS 
at RT for 15 minutes and washed three times with PBS for 5 minutes. Blocking solution 
(normal host serum of secondary antibody diluted 1:20 in PBS) was then applied for 1 
hour at RT. Primary antibody (anti-ALK5 (Abcam) 1:100 diluted in blocking solution) 
was applied at RT for 1 hour or at 4°C overnight. After three washes in PBS, secondary 
antibodies (Alexa Fluor-488, Invitrogen) were diluted 1:1000 in blocking solution and 
then applied to the cells for 45 minutes at RT. Samples were then counterstained with 
DAPI at RT for 5 minutes, washed three times with PBS and mounted with Fluorescent 
mounting medium (Dako). 
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2.7 Morphological analysis of human endothelial cells 
 
The quantification of cell elongation in HUVECs was performed using bright-field cell 
culture images (10 X magnification). A minimum of three images for each culture 
condition was used for analysis. Images were opened with the ImageJ software 
(http://fiji.sc/Fiji) and converted to 8-bit. The threshold was then automatically adjusted 
and in some cases manually optimized for better cell borders visualization.  Thresholded 
images were then analysed through the ImageJ function “Analyse particle” with the 
following optimized parameters: size (µm2) = 275-1200, circularity = 0-1 and “Exclude 
on Edges” (see Figure 22 for an illustrative example).  The average values of the function 
“round” (4 × [Area] / π × [Major axis] 2) were then selected for analysis. Some figures in 
the Results chapter show “elongation values”, which are the inverse of the round values 
described above.   
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Chapter III – Results: role of HDAC3α isoform in endothelial-





As discussed in ‘1.5 Project Background’, the HDAC3 gene generates several protein 
isoforms through alternative splicing. One of these isoform, HDAC3α, was found to 
induce a phenotype related to the endothelial-mesenchymal transition (EndMT). The 
EndMT is a cellular process in which ECs lose their specific markers and transform into 
mesenchymal cells, and is responsible for the formation of cardiac valves during 
embryonic development. Importantly, EndMT has been proposed to be reactivated in 
cardiac fibrosis and other cardiovascular diseases. Indeed, a relevant fraction of collagen-
producing fibroblasts that accumulate in fibrosis is thought to emerge from the 
endothelium via EndMT (see Figure 8 for a summary). Therefore, the hypothesis is that 
the splicing of HDAC3 induce EndMT, either in cultured ECs or in vivo. The 
characterization of this cellular process may shed light on the complex mechanisms 
underlying tissue remodelling and could provide avenues for therapeutic intervention. 
 
 
The aims of this result section are: 
 
 To investigate the mechanisms through which HDAC3α induces the EndMT and 
to identify the upstream factors responsible for the splicing of HDAC3 
 
 To determine the role of  HDAC3α in EndMT in vivo through a mouse model of 
cardiac fibrosis 
 


















Figure 8: Developmental EndMT is reactivated in adult tissues and gives rise disease-
associated fibroblasts. Schematic representation of the EndMT process responsible for the 
development of heart valves during cardiogenesis. This process has been proposed to occur in 
adult endothelial cells during disease with the downregulation of endothelial-specific markers and 
acquisition of mesenchymal ones, leading to their conversion into fibroblasts. The figure was 







3.2.1 HDAC3α isoform expression is induced in pressure-overload mouse hearts. 
 
 To investigate the involvement of HDAC3α in cardiac fibrosis, a pressure-overload 
mouse model was used. C57B1/6 mice were subjected to transverse aortic constriction 
(TAC) and cardiac samples were harvested at different time points after operation (see 
section 2.1.1). Collagen proteins were visualised by picrosirius-red staining, which 
reflected the extent of fibrosis. As shown in Figure 9, TAC induced fibrosis in the 
perivascular (top panels) and interstitial (bottom panels) cardiac areas as compared to the 
sham control. 
To determine whether TAC-induced cardiac fibrosis was related to EndMT, the 
expression levels of EndMT-related genes were compared between sham and TAC groups 
by qPCR analysis in cardiac samples collected at 3, 7 and 14 days after surgeries. As 
shown in Figure 10, no significant changes were detected in both endothelial (eNOS, VE-
Cadherin) and mesenchymal markers (αSMA, FSP1), possibly due to only a small subset 
of cardiac cells that have undergone EndMT. The only up-regulated gene in the TAC 
cardiac samples was collagen type I alpha I (COL1A1), consistent with the increased 
collagen staining observed with picrosirius-red-stained TAC heart section. 
In addition, the expression levels of HDAC3 and HDAC3α were analysed by Western 
blot in tissue lysates from different time points (Figure 11). HDAC3α was increased in 
TAC samples compared to sham controls, with a stronger induction at day 14. Conversely, 
the main HDAC3 isoform was slightly reduced in the TAC samples. These results suggest 
that a shift in the splicing of HDAC3 may occur in the pathological conditions and the 






















Figure 9: Aortic banding induces the development of cardiac fibrosis. Representative images 
of paraffin heart sections collected at 7 days after aortic banding were stained for collagen with 











Figure 10: TAC induces collagen I expression in mouse hearts. Quantitative RT-PCR analysis 
was performed on total RNAs isolated from sham and TAC heart tissue samples. mRNA 
expression of each EndMT marker was represented as fold induction relative to the corresponding 
levels in sham samples. Data is presented as mean±SEM and all values were normalised with the 
expression of the housekeeping gene (18s). Day 3: sham n=8, TAC n=8; day 7: sham n=7, TAC 








Figure 11: TAC induces HDAC3α expression in mouse hearts. Western blot analysis was 
performed on total protein lysates from heart tissues, which were collected at 7 and 14 days after 
aortic banding. The expression of GAPDH was used as a loading control. Blots are representative 





To further confirm the induced expression of HDAC3α in TAC samples, frozen sections 
from sham and TAC mouse hearts (day 7 after TAC) were analysed by 
immunofluorescence staining. Positive green signal corresponding to the antibody against 
HDAC3α was detected in TAC sections but not in sham controls (Figure 12). Double 
staining with the endothelial marker CD31 (Pecam1) indicates that HDAC3α may be 
localized in proximity of vessels, although further confocal microscopy analyses would 








Figure 12: HDAC3α expression in mouse hearts may localise to vessels. Cryosections of 
mouse hearts were collected at 7 days after TAC and stained with antibodies against HDAC3α 
and Pecam1. Cell nuclei were counterstained in blue with DAPI (Scale bars: 70μm). Images are 





3.2.2 TGFβ signalling is potentially involved in the alternative splicing of HDAC3 
 
TGFβ1 has been found as one of the main inducers of the EndMT both in vitro and in 
vivo during the development of cardiac valves (134). The key questions are from where 
this growth factor is derived and whether it contributes to cardiac fibrosis in vivo.  
Recently it has been found that platelets release TGFβ1 in plasma after aortic-constriction 
and that megakaryocyte-specific TGFβ1 knock-out mice display reduced cardiac fibrosis 
(135). Given these crucial roles in EndMT and TAC-induced pathological changes in 
heart, we then hypothesised that TGFβ signalling might constitute the upstream signal 
leading to the splicing of HDAC3. Consistent with our hypothesis, type I TGFβ receptor 
(TβRI) has been recently found to regulate RNA processing in cancer cells (136). Upon 
binding, TβRI translocates into the nucleus where it induces the alternative splicing of 
epidermal growth factor receptor (EGFR).  
To test whether a similar mechanism occurred in ECs, HAECs were treated with TGFβ1 
and 2 and stained with the antibody against TβRI (ALK5). Confocal images in Figure 13 
show that TβRI green signal increases in the nucleus when cells were treated with TGFβ1, 
while in presence of TGFβ2 it localised prevalently to the cytoplasm. This result indicates 
that, similar to cancer cells, the activation of TGFβ signalling can lead to the translocation 
of type I TGFβ receptor in the nucleus of ECs, where it may mediate different nuclear 

































Figure 13: TGFβ1 induces ALK5 nuclear translocation in HAECs. HAECs were treated with 
BSA, TGFβ1 and 2 (10 ng/ml) for 24 hours and the expression of TGFβ type 1 receptor (ALK5) 
was analysed by immunofluorescence staining. Cell nuclei were counterstained in blue with 
DAPI. Images were acquired through confocal microscopy. Scale bars: 25 μm. Images are 






To check whether TGFβ could induce the alternative splicing of HDAC3, mouse cells 
derived from aortic adventitia (see section 2.2.3) were treated with TGFβ1, 2 and 3 for 
24 hours and HDAC3α protein expression was analysed by Western blot (Figure 14). All 
three TGFβ isoforms up-regulated the expression of αSMA and only TGFβ1 induced a 
slight increase of HDAC3α protein expression. However, this result can only provide 
some preliminary mechanistic information about the ability of TGFβ1 to induce the 
splicing of HDAC3α. Given the high basal expression of αSMA in BSA control, these 
cells are likely to be smooth muscle cells. The occurrence of TGFβ1-induced HDAC3 
















Figure 14: Western blot analysis of HDAC3α and αSMA protein expression in mouse 
adventitia cells treated with TGFβs. Total proteins were extracted from mouse cells derived 
from aortic adventitia treated with either 10 ng/ml of BSA or TGFβ1, 2, 3 and then analysed by 
Western blot with antibodies against HDAC3α and αSMA. GAPDH protein expression was used 




3.2.3 TGFβ and Akt signalling pathways are involved in HDAC3α-induced EndMT 
 
Multiple signalling pathways such as TGFβ, Map kinase, PI3K/AKT, p38, JNK and Rho 
have been reported to be involved in the EndMT process (see section 1.3.2). To determine 
which signalling pathways are involved in HDAC3α-induced EndMT phenotype, 
HDAC3α was overexpressed in HAECs through infection with Ad-HDAC3α virus in the 
presence of selective chemical inhibitors. The protein expression level of αSMA was the 
read-out of the experiment since it is consistently up-regulated by HDAC3α 
overexpression (see section 1.5.2). Both TGFβ and PI3K/AKT inhibitors (SB431542 and 
LY294002, respectively) abolished Ad-HDAC3α-induced αSMA expression, while other 



















Figure 15: Western blot analysis of αSMA protein expression in HAECs infected with Ad-
HDAC3α virus in the presence of signalling pathway inhibitors. HAECs were infected with 
Ad-HDAC3α virus (10 MOI) in the presence of 10μM of chemical inhibitors indicated. Ad-null 
infection was used as control. Protein level of αSMA was analysed by Western blot on total 
proteins extracted 72 hours after treatment with the inhibitors. The anti-Flag antibody was used 
to confirm the exogenous expression of HDAC3α protein expression. GAPDH expression was 





To confirm the effect of SB431542 and LY294002 inhibitors on HDAC3α-induced 
EndMT, an immunofluorescence analysis was performed in HAECs (Figure 16). In 
agreement with the Western blot results, the expression of αSMA (green signal) was 
significantly induced in HDAC3α-overexpressing HAECs treated with DMSO and 
markedly suppressed by both SB431542 and LY294002. HDAC3α-dependent 
downregulation of VE-Cadherin (red signal) was suppressed by SB431542 but not 
LY294002, which may suggest PI3K/AKT signalling to play a partial role in HDAC3α-
induced EndMT.  
Collectively, both Western blot and immunofluorescence results suggest that HDAC3α 











Figure 16: SB431542 and LY294002 inhibitors abolish Ad-HDAC3α-induced EndMT 
phenotype. HAECs were infected with Ad-HDAC3α or Ad-null virus (10 MOI) in the presence 
of 10μM of SB431542 and LY294002 inhibitors. DMSO was included as vehicle control. 72 hours 
after treatment cells were stained with antibodies against VE-Cadherin and αSMA. Cell nuclei 
were counterstained in blue with DAPI. (Scale bars: 15μm). Images are representative of at least 




3.2.4 Role of HDAC3α in the extracellular activation of TGFβ2 
 
The ability of SB431542 inhibitor to block HDAC3α-induced EndMT may lead to the 
assumption that the function of HDAC3α is to induce the expression and/or secretion of 
TGFβ cytokines, which might in turn act in an autocrine and/or paracrine manner to 
induce EndMT. Since SB431542 targets specifically TGFβ type I receptors (ALK4-5-7), 
it is reasonable to assume that the overexpression of HDAC3α increases the expression 
of their ligands, which would in turn induce EndMT through the TGFβ signalling. To test 
this hypothesis, mRNA expression levels of TGFβ 1, 2 and 3 were measured in Ad-null 
and Ad-HDAC3α-infected HAECs. As shown in Figure 17, no significant changes in 
gene expression levels were detected. Protein expression levels of TGFβ isoforms were 
then analysed in cell lysates and conditioned media. Endogenous protein levels of TGFβ1 
and 2 were not changed upon HDAC3α overexpression (Figure 18 A). The induction of 
TGFβ signalling was confirmed by the increased level of phospho-SMAD2 in DMSO-
treated cells, which was suppressed by inhibitors of Akt (LY294002) and TGFβ 
(SB431542) signalling pathways. In conditioned media (Figure 18 B), protein levels of 
TGFβ1 slightly decreased in Ad-HDAC3α-infected cells compared to Ad-null control 
cells. In DMSO-treated Ad-null control cells, antibody against TGFβ2 detected a 
prevalent band of 50 kDa and a weaker band of 26 kDa. 50 kDa is the expected protein 
size of the TGFβ2 precursor while 26 kDa corresponds to the homodimeric active form 
of TGFβ2. In HAECs infected with Ad-HDAC3α virus the 50 kDa band decreased 
significantly, while the 26 kDa band of the active form was increased. This effect was 
abolished by LY294002, while the ratio between band intensities increased in favour of 
the 26 kDa band in the presence of SB431542, which is consistent with the extracellular 
accumulation of the active ligand due to the blocking of TGFβ type I receptor. These 
results thus suggest that HDAC3α mediates the activation of TGFβ2 in the extracellular 
space. To check whether this activation was required to induce the EndMT, HDAC3α-
infected HAECs were treated with the neutralization antibody against TGFβ2. As shown 
in Figure 19, the treatment with anti-TGFβ2 antibody impaired the upregulation of αSMA 
protein expression, thus suggesting that the cleavage and activation of TGFβ2 may be a 























Figure 17: Ad-HDAC3α has no effect on TGFβ1-3 mRNA expression. HAECs were infected 
with Ad-null or Ad-HDAC3α (10 MOI) for 6 hours and then cultivated in serum-free medium for 
72 hours. Quantitative RT-PCR analysis was performed on total RNA extracts to measure gene 
expression levels of TGFβ1, 2, 3 and exogenous HDAC3α. All values were normalized against 
the expression of 18s housekeeping gene. Error bars represent the mean (±SEM) of 2 independent 











Figure 18: Overexpression of HDAC3α induces TGFβ2 cleavage in HAECs. HAECs were 
infected with Ad-HDAC3α or Ad-null virus (10 MOI) in the presence of 10μM of DMSO, 
SB431542 and LY294002. Western blot analysis was performed on total proteins extracted from 
cell lysate (A) or conditioned media (B) 72 hours after inhibitors treatment. Antibody against 
pSmad2 was used to detect TGFβ signalling activation. The anti-Flag antibody was used to 
measure exogenous HDAC3α protein expression. GAPDH and Collagen IV expression were used 
as a loading control in cell lysate and conditioned media, respectively. Blots are representative of 
















Figure 19: The anti-TGFβ2 neutralization antibody abolishes HDAC3α overexpression-
induced SMA expression. HAECs were infected with Ad-HDAC3α or Ad-null virus (10 MOI) 
in the presence of 0.2 µg/ml of goat IgG (Immunoglobulin G) or 0.2 µg/ml of goat anti-TGFβ2 
antibody. Western blot analysis was performed 72 hours after treatment. Antibody against pSmad2 
was used to detect TGFβ signalling activation. The anti-Flag antibody was used to measure 
exogenous HDAC3α protein expression. GAPDH was used as a loading control. Blot is 
representative of at least three independent experiments.  
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3.2.5 Upregulation of ADAMTS1 by HDAC3α and its potential role in the activation 
of TGFβ2 
 
The extracellular activation of TGFβs is relatively less characterised compared to the 
intracellular signalling triggered by these cytokines. In the extracellular matrix, a central 
activation mechanism is the proteolytic cleavage of the latent-TGFβ complex, which 
makes the active TGFβ form able to bind to its receptors. Key regulators of this process 
are extracellular matrix proteases such as plasmin, matrix metalloproteases (MMPs) and 
thrombospondin-1 (137). In a microarray analysis previously performed in my host 
laboratory, different genes were found to be differentially regulated in HAECs by the 
overexpression of HDAC3α. One of the genes that showed a significant upregulation was 
ADAMTS1. ADAMTS (a disintegrin and metalloproteinase with thrombospondin 
motifs) gene family comprises multi-domain secreted proteins involved in a variety of 
functions, such as angiogenesis, blood coagulation and extracellular matrix homeostasis 
(138). Interestingly, ADAMTS1 has been recently found to directly associate and cleave 
the latent-TGFβ complex, contributing to the TGFβ-induced tissue remodelling in liver 
fibrosis (139). This evidence made ADAMTS1 a good candidate for the cleavage of 
TGFβ2 latent form described above. To confirm the microarray results, ADAMTS1 gene 
expression was compared in Ad-null and Ad- HDAC3α-infected HAECs by qPCR. As 




































Figure 20: Overexpression of HDAC3α increases ADAMTS1 expression in HAECs. Cells 
were infected with Ad-null or Ad-HDAC3α virus (10 MOI) for 6 hours and then cultivated in 
serum-free medium for 72 hours. Quantitative RT-PCR analysis was performed on total RNA 
extracts to measure gene expression levels of ADAMTS1. Values represent the fold induction 
against Ad-null control and are normalised against the expression of 18s gene. Error bars represent 














In this result chapter, the ability of the splicing isoform HDAC3α to induce the EndMT 
was investigated. The molecular mechanisms underlying the function of HDAC3α and its 
relevance in vivo can be summarised in the following conclusions: 
 
 TGFβ and Akt signalling pathways mediate the EndMT phenotype induced by 
the overexpression of HDAC3α in human ECs 
 
 The extracellular activation of TGFβ2 and its autocrine signalling determine the 
HDAC3α-mediated EndMT 
 
 Overexpression of HDAC3α upregulates gene expression of ADAMTS1, which 
may cleave extracellularly the latent complex of TGFβ2 
 
 In a mouse model of cardiac fibrosis, HDAC3α protein expression is induced in 



























3.4.1 A splicing isoform of HDAC3 induces EndMT in vitro. What are the molecular 
events involved? 
 
Previous work from the host laboratory revealed that during endothelial differentiation of 
mouse embryonic stem cells, the HDAC3 gene gave rise to different isoforms. One of 
these isoforms, named HDAC3α, was further reported to be involved in the endothelial 
mesenchymal transition (EndMT). When over-expressed in HAECs through adenoviral 
transfection, the phenotype obtained was in fact reminiscent of an EndMT: HAECs 
presented an altered morphology compared to control cells (empty adenovirus) and 
increased protein expression of mesenchymal markers, e.g. αSMA, N-cadherin and 
Snail2 (see section 1.5.2) (140). 
 
It was initially sought to characterise the molecular events involved in HDAC3α-induced 
EndMT. Using different chemical inhibitors of major signalling pathways, TGFβ and 
AKT signalling were found to be implicated in the emergence of the EndMT phenotype 
(3.2.3). The TGFβ signalling was further investigated due to its established role in both 
EndMT and cardiac fibrosis. By analysing the secreted proteins of HDAC3α-
overexpressing HAECs, it was found that HDAC3α did not change the gene expression 
levels of TGFβ ligands but induced instead the activation of the latent form of TGFβ2 in 
the extracellular space (3.2.4). Accordingly, the blockage of TGFβ2 with the 
neutralization antibody abolished HDAC3α-induced EndMT. These results indicate that 
HDAC3α could act upstream of TGFβ signalling and its function might be to release the 
active form of the cytokines from the extracellular matrix. This mechanism may be 
relevant for cardiac fibrosis as in lung and skin the fibrotic process occurs through the 
activation of latent TGFβ complex in the extracellular matrix rather than through 
transcriptional increase (141). To mediate the extracellular activation of TGFβ2, 
HDAC3α may increase the secretion of factors that cleave proteolytically the latent form, 
such as proteases. Further data supported this hypothesis: qPCR analysis showed that the 
overexpression of HDAC3α in HAECs increases gene transcription of ADAMTS1 
(3.2.5). Interestingly, this metalloproteinase was previously reported to directly interact 
and to activate TGFβ1 in liver fibrosis trough a proteolysis-independent conformational 
mechanism, a process similar to the thrombospondin-mediated TGFβ activation (139). 
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These data thus suggest that in addition to the role in EndMT, the splicing of HDAC3 
may be involved more broadly in the remodelling of extracellular matrix through the 
regulation of cytokines turnover.  
 
Another aspect covered in the project was to definition of the regulatory mechanisms 
leading to the splicing of HDAC3α. Following the general principle  according to which 
alternative splicing is influenced by external growth factors (142), the working hypothesis 
formulated was that TGFβ signalling could itself induce HDAC3α splicing. This 
hypothesis was also consistent with a recent study showing that in cancer cells the TGFβ 
receptor 1, upon TGFβ1 binding, translocates into the nucleus and regulates RNA 
processing (136, 143). Accordingly, data obtained in HAECs showed that TGFβ1 but not 
TGFβ2 induced the translocation of TGFβ receptor 1 into the nucleus (3.2.2. However, 
whether TGFβ1 has the ability to induce HDAC3 splicing in ECs hasn’t been 
demonstrated. Results obtained in a different cell type, i.e. mouse adventitia-derived cells, 
provided a preliminary mechanistic indication that needs further investigation. 
Nonetheless, in light of the reported extracellular activation of TGFβ2, the potential 
induction of HDAC3 splicing by TGFβ1 would configure a feedback loop regulatory 
mechanism between the two isoforms. This speculation fits in the context of 
understanding the individual functions of TGFβ isoforms, which have already been 
shown to differentially regulate distinct phases of EndMT during cardiogenesis (134).  
 
 
3.4.2 Is HDAC3α expressed in vivo? 
 
The in vitro molecular studies of HDAC3α function during EndMT have been performed 
in parallel with in vivo experiments, which aimed at determining the presence of this 
protein in cardiac tissues and specifically, the link between HDAC3α and cardiac fibrosis 
(3.2.1). To this end, transverse aortic constriction (TAC) pressure-overload mouse model 
was used. The occurrence of fibrosis was confirmed by histological staining of collagen 
proteins in heart sections. However, quantitative RT-PCR analysis did not detect changes 
in gene expression of EndMT-associated markers. This can be explained considering that 
potential transcriptional changes in a small subset of cells may be masked when an entire 
tissue is analysed. Nevertheless, Western blot analyses showed that HDAC3α protein 
expression was increased in fibrotic hearts compared to sham control, while on the other 
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hand, the expression of HDAC3 was reduced. This balance between HDAC3 isoform 
during fibrosis provides an interesting clue on how HDAC enzymes may function in 
tissue remodelling. Furthermore, immunofluorescence staining of HDAC3α in the 
fibrotic and sham hearts was performed to clarify whether its expression was localized in 
ECs. Results confirmed an overall increase in HDAC3α expression in TAC samples 
compared to sham but they were unable to unequivocally demonstrate its cellular location. 
Therefore, in order to support a role of HDAC3α in EndMT-induced cardiac fibrosis, 




3.4.3 HDAC3α: critical points to address  
 
Overall, the results obtained in vivo and in vitro offer interesting clues about the function 
of HDAC3α during EndMT and its potential role in cardiac fibrosis. However, it is worth 
to point out key questions that need to be addressed in the future in order to support the 
relevance of this new HDAC3 isoform. Firstly, most in vitro experiments relied on the 
overexpression of HDAC3α through adenoviral transfection, a system which may 
confound the analysis of specific phenotypes given the reported side effects of 
adenoviruses on endothelial cell physiology (144). In this regard, a functional 
investigation of the endogenous HDAC3α would be preferable. This option has however 
proven to be challenging because mouse ECs are technically difficult to grow in culture. 
Moreover, initial experiments in both primary and immortalized mouse ECs have not 
provided a clear indication of what conditions induce the splicing of HDAC3α. 
Determining the conditions that give rise to the endogenous HDAC3α is therefore critical 
to understand the real physiological role of this isoform and the underlying mechanisms.                 
Secondly, HDAC3α is a mouse-specific isoform; an analysis of the nucleotide sequence 
corresponding to the intron-12 of the HDAC3 gene reveals in fact that this genomic region 
varies greatly across different mammalian species. Since intron-12 sequence gives rise to 
the c-terminal of mouse HDAC3α and is therefore functionally important (see section 
1.5.1), its non-conservation would argue against a functional role generalizable to other 
species, thus challenging the biological and biomedical relevance of this protein. 
Nonetheless, it may be possible that in human, for instance, other isoforms could play 
similar roles of HDAC3α, regardless of the precise mechanism of splicing. The 
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identification of these putative human isoforms with equivalent roles in EndMT would 






























TGFβ signalling has been the most prominent mechanisms described for EndMT in 
developmental and in vitro studies. However, whether TGFβ growth factor molecules are 
both necessary and sufficient to drive the EndMT — or whether other factors are capable 
of inducing it — is currently less well-known. Also, as described in ‘1.3.2 Literature 
review of EndMT’, in vitro studies have reported conflicting results on the ability of 
TGFβ ligands to induce morphological changes in ECs.  
In the EMT, the interplay between TGFβ-induced responses and inflammatory 
mechanisms are at the root of the cellular effects responsible for pathological processes 
(145). Similarly, the disorders in which EndMT has been shown to play a role (e.g. cardiac 
and renal fibrosis and neointima) are characterized by a strong inflammatory response.  
The molecular mechanisms linking the mesenchymal transition of ECs to inflammation 
have not been extensively studied; thus, it was hypothesized that inflammatory cytokines 
such as TNF and IL1β induce EndMT.   
 
The aims of this result section are: 
 
 To determine whether inflammatory cytokines induce a fibroblast-like 
morphology in ECs in vitro, comparing their effect to TGFβ. 
 
 To analyse the expression changes of EndMT-related genes in ECs upon treatment 
with inflammatory cytokines 
 
 To investigate the structural effect of inflammatory cytokines on the cytoskeleton 









4.2.1 Morphological changes of endothelial cells treated with different inflammatory 
cytokines. 
 
In order to determine what factors induce a consistent mesenchymal phenotype in ECs, 
HUVECs were treated with different cytokines which have been previously reported to 
induce changes in endothelial cell morphology: TGFβ2, TNF and IL1β (54, 146, 147). 
Since synergistic effects have been reported for these factors, all possible combinations 
were examined. 
In the control condition (see section 2.2.2), confluent HUVECs were densely packed and 
displayed a round phenotype, the so-called “cobblestone” morphology. Treatment with 
TGFβ2 did not alter this cellular architecture, whereas the same concentration of either 
TNF or IL1β changed cell morphology, with cells acquiring an elongated shape (Figure 
21). The combination of TNF and IL1β further increased this elongation with cells being 
more uniformly spindle-shaped. The combinations TNF+TGFβ2 and IL1β+TGFβ2 did 
not increase significantly the elongation compared to TNF or IL1β alone and an increase 
in cell death seemed to be present. In the presence of all three cytokines together, cell 
elongation appeared similar to TNF+IL1β, although thin cellular protrusions were present 
in some cells. 
Quantification of cell elongation shown in Figure 23 was consistent with the morphology 
observed through bright-field images (see Figure 22 and section 2.7 for method details). 
Control and TGFβ2-treated HUVECs returned the highest round values among the 
different conditions, while TNF and IL1β increased cell elongation and thus presented 
lower values. The combinations TNF+IL1β and TNF+IL1β+TGFβ2 gave rise to the 
highest cell elongation, with mean round values of 0.3±0.01 and 0.29±0.01, respectively. 
Taken together, these data show that the inflammatory cytokines TNF and IL1β are able 
to induce a consistent morphological change in HUVECs, which loose the round 
cobblestone phenotype and acquire an elongated spindle-shape. This effect is 
synergistically increased in the presence of both cytokines. On the other hand, TGFβ2 




Figure 21: Effect of different combinations of cytokines on endothelial cell morphology. 
Representative cell culture images of HUVECs monolayers treated with different combinations 
of cytokines for 48 hours. Each cytokine was added at a concentration of 10 ng/ml. Images are 













Figure 22: Morphological analysis of cytokine-treated endothelial cells. Representative 
example of image processing in cytokine-treated HUVECs. Bright field cell culture images were 
threshold-adjusted (upper panels) and the borders of individual cells were automatically detected 






Figure 23: Quantification of cell elongation in cytokine-treated endothelial cells. Multiple 
cell culture images of each cytokine combination (as represented in Figure 21) were processed 
with ImageJ software and mean round values were calculated (see Figure 22 and section 2.7 for 
method details). Round measures how shapes approach a perfect circle (= 1). A) Box Plot analysis 
of a single representative experiment highlighting value distribution and sample size of each 
condition. B) Mean round values ±S.D. (Standard deviation) of two independent experiments. * 
P-value < 0.05, ** P <0.01, as calculated against the control using the Student’s t-test.   
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4.2.2 Gene expression analysis of EndMT markers in cytokine-treated endothelial 
cells 
 
The acquisition of mesenchymal features in ECs is thought to be driven by dramatic 
changes at the level of gene expression. Different genes have been reported to be either 
down- or upregulated. To check whether the cytokine-induced shape changes observed in 
ECs correlated with transcriptional regulation of EndMT markers, a quantitative RT-PCR 
analysis was performed in HUVECs. The graph in Figure 24 shows the expression levels 
of three endothelial-specific (VE-Cadherin, PECAM1, eNOS,) and three mesenchymal-
specific markers (S100A4, N-cadherin, ACTA2). Relative to the control, there was no 
significant difference in mRNA abundance of VE-cadherin and PECAM1 in any of the 
conditions tested, while the expression of eNOS was downregulated less than 2-fold in 
HUVECs treated with IL1β or TNF+IL1β. The combined TNF+IL1β+TGFβ2 treatment 
induced the highest downregulation of eNOS, with almost 5-fold compared to control. 
The gene expression levels of mesenchymal markers showed a moderate upregulation in 
some of the conditions tested. Compared to untreated cells, the expression of S100A4 
was induced by almost 3 folds by TNF or TNF+IL1β, while there was little difference in 
the remaining conditions. N-cadherin expression was upregulated in TNF- and 
TNF+IL1β+TGFβ2-treated cells by approximately two and three folds, respectively. The 
expression of ACTA2 was increased by 3 folds by TNF and to a lesser extent, by IL1β 
and TNF+IL1β+TGFβ2. 
Taken together, these data do not reflect a loss of endothelial-specific proteins and an 
acquisition of mesenchymal-specific ones, a pattern that is considered a hallmark of the 
endothelial-mesenchymal transdifferentiation. With the exception of eNOS, the       
expression of the endothelial markers remains stable in all the conditions tested, whereas 
the mesenchymal markers show variable and modest upregulations. The latter effect may 
be due to either an indirect transcriptional effect induced by TNF and/or IL1β or simply 












Figure 24: Gene expression analysis of EndMT markers in cytokine-treated endothelial 
cells. HUVECs were treated for 48 hours with different combinations of cytokines and RNA was 
analysed through quantitative RT-PCR. mRNA expression levels represent fold changes relative 
to untreated cells (CTRL). All values were normalized against the expression of the RPL13A 
housekeeping gene and represent the mean ±S.D (n=3). ** P < 0.01, * P < 0.05; for all other 




To check whether the lack of gene expression differences of endothelial markers is 
reflected in protein levels, HUVECs were treated with cytokines for 48 hours and protein 
extracts were analysed by Western blot (Figure 25). Consistent with qPCR data, there was 
no significant difference in VE-Cadherin protein expression in all conditions tested. 
Furthermore, the expression of eNOS was decreased in all conditions except TGFβ2, 













Figure 25: Protein expression analysis of endothelial markers in cytokines-treated 
endothelial cells. HUVECs were treated for 48 hours with different combinations of cytokines. 
Protein lysates were then analysed through Western blot. GAPDH was used as the loading control. 




4.2.3 Role of TGFβ2 in cytokine-induce elongation of ECs 
 
The inability of TGFβ2 to induce EndMT features, such as cell morphology and 
gene/protein expression changes, despite its prominent role in EndMT described in 
literature, prompted to investigate whether its signalling pathway is active in the current 
cellular model. To this end, TGFβ2-treated HUVECs were analysed by Western blot to 
detect the phosphorylation of Smad2, an essential transducer for TGFβ signalling (148). 
The results shown in Figure 26 indicate that TGFβ2 robustly induces Smad2 
phosphorylation 1 hour after treatment and this effect persists after 24 hours. The 
expression of total Smad2 wasn’t changed significantly, suggesting that the 
phosphorylation is directly induced by TGFβ2 and not due to an increase in the amount 
of total protein. On the other hand, in the presence of TNF and IL1β, Smad2 was not 
phosphorylated, thus ruling out the possibility that these inflammatory cytokines could 
activate indirectly the TGFβ signalling. Furthermore, the baseline Smad2 
phosphorylation appeared to be inhibited at 1 hour by TNF+IL1β, in agreement with 
studies in other cell types showing an antagonist effect inflammatory cytokines on TGFβ 
signalling (149, 150). In the presence of all three cytokines (TNF+IL1β+TGFβ2) there 
was no further increase in the phosphorylation of Smad2 compared to TGFβ2 alone. The 
activation of Smad2 by TGFβ2, furthermore, was confirmed to be mediated by the ALK5, 
since the phosphorylation was totally inhibited at both time points in the presence of the 
SB431542, a chemical inhibitor specific for the type-1 receptor.  
Taken together, these results show that, under the current experimental settings, TGFβ2 
is biochemically active and the inflammatory cytokines do not transactivate the TGFβ-

















Figure 26: TNF and IL1β do not activate TGFβ signalling. HUVECs were treated with 
different cytokine for 1 and 24 hours and protein expression was analysed by Western blot. 
GAPDH expression was used as a protein loading control. SB431542 inhibitor was added at a 
concentration of 10 μM concomitantly with cytokines. Blots are representative of three 





To get further insights about the role of TGFβ signalling in cytokine-induced shape 
changes of ECs, SB431542 was added in combination with TNF and IL1β and cell 
elongation was quantified. Compared to control (DMSO), SB431542 treatment alone 
induced a slight increase in cell elongation (Figure 27). The presence of brighter light 
around the cell body suggest that this effect may be due to an alteration of cell junctions. 
Nonetheless, the elongation induced by SB431542 appeared phenotypically different 
from the one induced in TNF+IL1β-treated cells, which were instead characterised by an 
overall extension of the cell body. Interestingly, when ECs were treated with both 
SB431542 and TNF-IL1β, cell elongation reached its highest value and cells became 
extremely spindle-shaped, a morphology reminiscent of fibroblast cells.  
Overall, these results confirm the lack of effect of TGFβ signalling in inducing a 
mesenchymal-like phenotype. Conversely, the inhibition of TGFβ signalling enhanced 
cell elongation induced by TNF and IL1β, thus suggesting that TGFβ may act on ECs to 





Figure 27:  Inactivation of TGFβ signalling increases cytokine-induced cell elongation. A) 
Representative images of HUVECs grown to confluence and treated for 24 hours with 10 ng/ml 
of TNF and IL1β in the presence of SB431542 inhibitor or DMSO. Scale bar: 100μm. B) 
Quantification of cell elongation was performed on multiple images of each condition using 





The TGFβ signalling-dependent activation of transcription has been reported to play a 
significant role in the EndMT, with several mesenchymal genes dramatically induced and 
thus considered markers for the process (71, 72). The expression of two of those genes, 
SM22 (TAGLN) and PDFGβ, was then analysed in HUVECs treated with TNF and IL1β 
in the presence of SB431542 to check whether there was any correlation between 
increased transcription and morphological change. The expression of SM22 was 
moderately induced by almost 2.5 folds in TGFβ2-treated cells compared to control, while 
it was not increased by either TNF-IL1β or SB431542 (Figure 28). When HUVECs were 
treated with both SB431542 and TNF+IL1β, the expression of SM22 was downregulated 
by almost 5 folds compared to untreated cells. Thus, these results indicate that SM22 
expression does not correlate with cell elongation and that its transcription is not activated 
by inflammatory cytokines in ECs. On the other hand, the expression of PDFGβ was up-
regulated by TNF+IL1β by 4 folds compared to control, while there were no consistent 
changes in TGFβ2 or SB431542-treated cells. Interestingly, in the presence of SB431542 
inhibitor the effect of TNF-IL1β was abrogated.  
Taken together, these data show that PDFGβ expression is induced by pro-inflammatory 
cytokines and that this effect is dependent on TGFβ signalling. Yet, the increased 
expression does not seem to reflect the dramatic difference expected for newly acquired 



























Figure 28: Gene expression analysis of mesenchymal markers in cytokine-treated 
endothelial cells. HUVECs were treated with the indicated cytokines for 24 hours in the presence 
of the SB431542 inhibitor. Extracted RNA was analysed through quantitative RT-PCR. The 
mRNA expression levels were represented as fold change relative to control (DMSO). All values 
were normalized with the expression of RPL13A housekeeping gene and represent the mean 




4.2.4 Immunofluorescence staining of ECs treated with inflammatory cytokines 
 
To gain more insights into the morphological changes induced by pro-inflammatory 
cytokines in ECs, HUVECs were stained for F-actin and VE-Cadherin, two main 
constituents of the cytoskeleton and cell junctions, respectively. In the 
immunofluorescence pictures shown in Figure 29, the compact arrangement of untreated 
cells was dramatically altered by TNF+IL1β: cells became enlarged with disrupted cell 
junctions, although the expression of VE-Cadherin did not seem to be reduced 
significantly. Moreover, F-actin staining of control cells highlighted the distribution of 
actin around the cytoplasm, while in the presence of TNF+IL1β actin filaments became 
predominantly parallel to the long cell body axis. Overall, these data suggest that pro-
inflammatory cytokines induce extensive structural reorganisations in the actin 




























Figure 29: Immunofluorescent staining of HUVECs treated with inflammatory cytokines. 
Confluent HUVECs were either left untreated or stimulated with 10 ng/ml TNF+IL1β for 24 
hours. Cells were stained for F-Actin (red) and VE-Cadherin (green). Cell nuclei were stained 







In this result chapter, the effect of inflammatory cytokine treatment on EC morphology 
was examined in vitro. The results are summarized in the following points: 
 
 Both TNF and IL1β induce a consistent morphological change in ECs, 
determining the acquisition of a spindle-shape. Cell elongation is increased in 
presence of both cytokines. In contrast, TGFβ2 has no effect on EC morphology 
 
 TGFβ signalling is active in ECs and its blockage increases cytokine-induced cell 
elongation; it may thus preserve vessel integrity in inflammatory conditions  
 
 Gene expression analysis of endothelial and mesenchymal markers in presence 
of inflammatory cytokines does not suggest the transition of ECs into a 
mesenchymal cell type 
 
 TNF and IL1β induce the rearrangement of the actin cytoskeleton of ECs and the 





















4.4.1 What factors induce EndMT in vitro? 
 
ECs cultured in vitro have been shown to recapitulate the EndMT occurring in vivo during 
fibrosis, thereby offering the opportunity to decipher the underlying molecular 
mechanism and to find potential therapeutic targets. The key factor that has been shown 
to induce EndMT in vitro is TGFβ2 (67, 87). Contrary to these studies, results presented 
in this thesis do not support a role of TGFβ2 in inducing EndMT in human ECs (4.2.1). 
In the presence of this growth factor, HUVECs retain a rounded, cobblestone morphology 
and the expression of a panel of EndMT markers, as measured by quantitative RT-PCR, 
is not significantly changed. Moreover, the unaffected expression of the endothelial 
specific marker VE-Cadherin was also confirmed at protein level. The discrepancy 
between these data and those reported in previous publications (54, 67, 87) may have 
different explanations. First of all, the experimental setting used in this study is different 
from those in the aforementioned publications as HUVECs have been cultured with 
complete medium, thus in the presence of different growth factors that could interfere 
with the analysis. To induce EndMT, Medici et al. cultured HUVECs for 72 hours in 
serum-free medium (67, 87). Initial experiments aiming at reproducing this protocol 
failed as in the serum-free condition most HUVECs died within 24 hours. The use of 
complete medium was then adopted to overcome this limitation. Nonetheless, further 
analyses showed that TGFβ signalling was biochemically active in HUVECs; upon 
cytokine/growth factor treatment, Smad2 phosphorylation was increased and downstream 
target genes were transcriptionally increased. Taken together, these data suggest that 
TGFβ2 is not able to induce the EndMT in human ECs. 
Although in conflict with recent influential publications and related reviews putting the 
TGFβ-EndMT axiom forward, the results obtained here are consistent with other reports 
in the literature that examined the effect of TGFβ in ECs. For instance, several studies 
failed to induce morphological change and/or expression of αSMA in different types of 
human ECs, including HUVECs, HAECs and HMECs (60, 63, 64, 151). The inability of 
TGFβ alone to induce EndMT was also reported in earlier studies of endocardial cushions 
formation that highlighted instead how multiple factors and related signalling pathways 
are necessary for the different steps of endothelial transdifferentiation (152, 153). 
Furthermore, experiments with TGFβ inhibitors in combination with inflammatory 
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cytokines  suggested that constitutive TGFβ signalling may actually serve to maintain the 
integrity of endothelial junctions, in agreement with other reports showing its role in 
vascular integrity (see next section) (154, 155).      
 
 
4.4.2 Inflammatory cytokines induce a morphological change in human endothelial 
cells: is this an EndMT? 
 
A recent study reported that inflammatory cytokines such as TNF and IL1β could induce 
the EndMT in intestinal ECs, describing this process “inflammation-induced EndMT” 
(156). The results obtained here reveal that both TNF and IL1β significantly increased 
cell elongation of HUVECs, as assessed quantitatively through a morphological analysis 
on bright-field cell culture images (4.2.1). Furthermore, cell elongation was further 
increased when both TNF and IL1β were added together. This indicates a synergistic 
effect among cytokines, consistent with previous studies (156, 157). To check whether 
this observed phenotype could be interpreted as an EndMT, the expression of several 
EndMT-related markers were measured in HUVECs treated with different combinations 
of inflammatory cytokines. Upon 48 hours treatment, no significant changes were 
observed in the expression of the endothelial markers VE-Cadherin and Pecam1 in any 
of the conditions tested, whereas eNOS was downregulated when all cytokines where 
administered together. The expression of classical mesenchymal markers, e.g. αSMA, 
FSP1 and N-cadherin, was also unaltered in the presence of cytokines (4.2.2). The 
unchanged expression of VE-Cadherin was also confirmed by Western blot analyses and 
immunofluorescence staining. Thus, these results suggest that the fibroblast-like 
elongation phenotype induced by inflammatory cytokines is not consistent with the 
EndMT. Interestingly, when HUVECs were stimulated with TNF+IL1β in the presence 
of the TGFβ inhibitor SB431542, cell elongation was further increased compared to 
TNF+IL1β treatment alone (4.2.3). Also, the administration of SB431542 resulted in 
altered cell junctions visible in bright field images as brighter light around cell borders. 
These results confirm on one hand the independence of the observed shape changes from 
TGFβ signalling and on the other hand, highlight the importance of the crosstalk between 
TGFβ and inflammatory signals in the maintenance of vascular integrity, as previously 
reported (154, 155).  
Furthermore, F-actin/VE-Cadherin immunofluorescence co-staining of TNF+IL1β-
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treated HUVECs revealed cytoskeletal rearrangements and formation of junctional gaps 
(4.2.4). Actin fibres, which were present around the cell cortex in untreated cells, formed 
long bundles parallel to the cell axis in the presence of inflammatory cytokines. These 
structural features are consistent with earlier studies showing a similar response of 
cytokine-treated human ECs (146, 158).  
Overall, in light of earlier literature the results obtained here suggest that the phenotype 
resulting from TNF+IL1β treatment can be interpreted as a structural cell remodelling 
rather than a differentiation towards different cell lineages such as fibroblast or smooth 
muscle cells. As described in the introduction (1.1.3.4) during inflammation the 
endothelium becomes “activated”, resulting in several biochemical and structural 
changes. Among these responses, the modulation of endothelial cell-cell junctions plays 
a prominent role as it facilitates the transmigration of  immune cells from the bloodstream 




Chapter V – Results: regulation cytokine-induced morphology 





Shape is an important indicator for cell physiology and is tightly controlled in 
development during tissue morphogenesis. The dramatic morphological changes of 
individual cells occurring in EMT during gastrulation are essential to drive the formation 
of germ layers. In ECs, shape changes correlate with the physiological status of blood 
vessels and are controlled by both cellular and environmental factors. For instance, 
hemodynamic forces generated by blood flow have been shown to induce dramatic 
morphological changes in ECs (159, 160). Both cytoskeletal rearrangements and external 
forces concur in cellular mechanotransduction, which is an emerging component of 
disease pathogenesis. 
EndMT have been often described with a consistent change of cellular shape. Conversion 
of the rounded (and static) phenotype — the cobblestone morphology — into a fibroblast-
like spindle shape, has been considered a hallmark of the mesenchymal transition (see 
section 1.3). EC undergoing EndMT acquire invasive and secretory properties that 
eventually contribute to fibrosis and other disorders.  
As shown in Chapter IV, inflammatory cytokines are also able to induce a morphological 
change in ECs, which is seemingly consistent with the EndMT reported previously; 
therefore, it was sought to identify the regulators of this phenotype, in order to shed light 
on the physiological and pathological relevance of this process.   
 
The aims of this result section are: 
 
 To identify cytokine-induced genes that might play a role in the morphological 
change of ECs in vitro  
 
 To dissect the inflammation-induced signalling pathways involved in the 





5.2.1 Role of the cytoskeletal regulator RND1 in endothelial cell elongation 
 
To find new potential mediators of the morphological changes of ECs, published 
microarray data of gene expression of inflammation-stimulated ECs were searched. One 
study presented an informative list of novel genes activated by TNF in human ECs (161). 
Among those genes, a GTP-binding protein was reported to be significantly induced by 
TNF, with a fold induction relative to control >5. This gene corresponds to the Rho-
GTPase RND1, a protein which was previously shown to be involved in the regulation of 
actin cytoskeleton (162). To confirm the transcriptional activation of RND1, HUVECs 
were stimulated with inflammatory cytokines and RND1 expression was analysed by 
qPCR at two different time points, 6 and 48 hours. As shown in Figure 30, RND1 
expression was dramatically increased 6 hours after treatment, with >20 folds induction 
in both TNF- and IL1β-treated cells. Interestingly, when cells were treated with both 
cytokines together the expression of RND1 raised to almost 80 folds compared to control, 
suggesting a synergistic effect of TNF and IL1β on its activation. However, due to high 
variability of expression levels, the differences between the conditions did not reach 
statistical significance. At 48 hours the expression of RND1 was still increased relative 
to control but all values were lower compared to the 6 hours time point. In TNF- and 
IL1β-treated cells RND1 expression reached a 5-fold change compared to control, while 
in cells treated with TNF+IL1β, similarly to the 6 hours time point, RND1 expression was 
further increased compared to cells treated with either cytokines alone (27-fold). These 
results thus indicate that RND1 is rapidly activated by an inflammatory stimulus in human 
ECs and notably, its expression seems to be synergistically increased by TNF and IL1β. 
This effect correlates well with the increased cell elongation induced by TNF+IL1β and 



















Figure 30: RND1 is upregulated in cytokine-treated human endothelial cells.  HUVECs 
were treated with TNF, IL1β or TNF+IL1β for 6 or 48 hours. Extracted RNA was analysed 
through quantitative RT-PCR. mRNA expression levels were represented as fold change relative 
to untreated cells (CTRL). All values were normalized with the expression of RPL13A 





To test the hypothesis that RND1 regulates the cytoskeletal rearrangements of ECs 
induced by inflammatory cytokines, a siRNA gene silencing approach was used. The 
activation of RND1 expression by TNF and IL1β was blocked through a siRNA pool that 
targets RND1 mRNAs. This inhibition was achieved with high efficiency, as in HUVECs 
treated with RND1 siRNA the expression of RND1 was reduced >90% compared to the 
baseline level of untreated cells (Figure 31). In unstimulated cells, the addition of RND1 
siRNA had no detectable effect on cell morphology (Figure 32 A). As expected, the 
addition of TNF and IL1β induced an increase in cell elongation. However, in the 
presence of RND1 siRNA, cell elongation was still higher than that in untreated cells and 
it was even slightly increased compared to inflammation-induced RND1-unsilenced cells 
(Figure 32 B). Therefore, these results refute the hypothesis that Rho-GTPase RND1 
regulates inflammation-induced cytoskeletal rearrangements of ECs. Nonetheless, the 
magnitude of cytokines-induced transcriptional activation of RND1 suggests potential 
























Figure 31: Efficiency of RND1 gene silencing in endothelial cells. HUVECs were treated with 
a combination of TNF and IL1β together with either RND1-targeting siRNAs or non-targeting 
siRNAs as a control. RNA from each condition was extracted 24 hours after treatment and 
analysed through quantitative RT-PCR. The mRNA expression levels were represented as fold 
change relative to siRNA no-target. All values were normalized with expression levels of the 
RPL13A housekeeping gene and represent the mean ±S.D. (n=3). P-values were calculated using 







Figure 32: RND1 gene silencing has no effect on cytokine-induced endothelial cell 
elongation. A) HUVECs were treated for with either RND1 siRNAs or non-targeting siRNAs as 
a control, together with a combination of the inflammatory cytokines TNF and IL1β. Cell culture 
images were acquired 24 hours after treatment. Scale bar: 100 μm. B) Quantification of cell 
elongation was performed on multiple images of each condition using ImageJ software (see 




5.2.2 Signalling pathways involved in endothelial cell elongation 
 
Several signalling pathways have been associated with the remodelling and dynamics of 
cell cytoskeleton (163). In order to define which signalling is involved in inflammation-
induced morphological changes of ECs, different chemical inhibitors were used to target 
specific proteins. A highly characterised regulator of the actin cytoskeleton is protein 
kinase ROCK (Rho-associated protein kinase), which is an effector in the Rho-signalling 
pathway and involved in different cellular functions, including cell shape, motility and 
migration(164). To check whether ROCK plays a role in the cell elongation observed in 
HUVECs, cells were stimulated with TNF and IL1β in the presence of the potent inhibitor 
Y27632 (165). Inhibition of ROCK had the visible effect of reducing cytokine-induced 
morphological rearrangement, which was confirmed by quantification of cell elongation 
(Figure 33). These results are consistent with earlier study showing a ROCK-mediated 
effect of TNF on the morphology of ECs (146, 158). Nonetheless, ROCK inhibition 
altered the cytoskeleton of HUVECs by inducing the formation of thin cellular 
protrusions, which seemed to increase in number upon TNF+IL1β stimulation (Figure 
34). In agreement with this, ROCK has been previously reported to limit membrane 
protrusion induced by integrins in leukocytes (166).       
To investigate additional components of the Rho-signalling pathway involved in the 
cytoskeletal rearrangements of HUVECs, cells were treated with inhibitors that target  
Rho GTPase family (RhoA, B, C) and Myosin Light Chain Kinase, which act upstream 
and downstream of  ROCK kinase, respectively. As shown in Figure 35, both inhibitors 
(C3 transferase and ML7) failed to prevent the cell elongation induced by TNF+IL1β. 
Inhibition of Rho gave rise to a significant cell shrinking and rarefaction of the 
cytoskeleton, while the inhibition of MLCK did not produce a discernible phenotype.   
These data indicate that although ROCK kinase has a consistent effect in TNF+IL1β-
induced endothelial cell elongation, the mediators that transmit the signalling to the 















Figure 33: ROCK inhibition abolishes TNF+IL1β-induced endothelial cell elongation. 
HUVECs were treated with a combination of TNF and IL1β in the presence of 5μM of ROCK1 
inhibitor Y27632. Control cells were treated with DMSO. Bright field images were acquired after 
24 hours. Scale bar: 100 μm. Quantification of cell elongation was performed on multiple images 












Figure 34: ROCK inhibition induces cell protrusions in endothelial cells. 20X magnification 
bright-field images of HUVECs treated with the ROCK inhibitor Y27632 (5µM) in the presence 
of TNF and IL1β (10ng/ml). Images were acquired at 24 hours post treatment. Black arrows 













Figure 35: Chemical inhibition of Rho signalling mediators has no effect on cytokine-
induced endothelial cell elongation. HUVECs were treated with a combination of TNF and IL1β 
in the presence of the RhoA, B, C inhibitor C3 transferase (1µg/ml) or the Myosin Light Chain 
Kinase (MLCK) inhibitor ML7 (10µM). Images were acquired at 24 hours post treatment. Scale 




5.2.3 Role of NF-κB signalling in cytokine-induced cell shape changes in endothelial 
cells 
 
The canonical signal transduction pathway triggered by the pro-inflammatory cytokines 
TNF and IL1β results in the activation of the transcription factor NF-κB, which in turn 
induces or represses the transcription of genes necessary for innate immunity and cell 
survival (167). In normal conditions, NF-κB is retained in the cytoplasm bound to the 
inhibitors IκB. In response to inflammatory stimuli, the enzymatic kinase complex IKK 
phosphorylates IκB, leading to its degradation and the consequent release of NF-κB. 
As shown in the time-course analysis in Figure 36, IκBα was rapidly degraded in 
HUVECs after 15 minutes of TNF+IL1β treatment. The protein level remained relatively 
low at 30 minutes, while after 1 hour, it returned of comparable levels to that of untreated 
cells. From 2 hours onwards, IκBα was robustly expressed at a higher level than that 
observed in control. These data suggest that the transcriptional activity of NF-κB is 
concentrated in a short time window and that after the initial stimulus, ECs may quickly 
become resistant to further signals by expressing the IκBα inhibitor.    
 
In order to investigate whether the modulation of NF-κB affects the morphological 
change of ECs, HUVECs were treated with the chemical inhibitor Wedelolactone, a 
natural molecule derived from the herbal medicine Eclipta alba that acts as a cell 
irreversible inhibitor of IKKα and β kinase activity (168). Cell culture images of 
HUVECs in Figure 37 show that the cytoskeletal rearrangements induced by TNF+IL1β 
were significantly reduced in the presence of the IKK inhibitor. Cell shape quantification 
further confirmed that the elongation scores of cytokine-stimulated HUVECs were 
similar to that of DMSO-treated cells.  
Taken together, these results indicate that NF-κB signalling is directly involved in cell 
shape changes of ECs through the activity of IKK kinases. It remains to be determined 
whether this function involves the NF-κB-dependent transcription or just the direct 
















Figure 36: TNF and IL1β induce a transient degradation of IκBα in endothelial cells. 
HUVECs were treated with a combination of TNF and IL1β for 15 minutes up to 48 hours. Protein 
lysates were collected at the indicated time points and subjected to Western blot analysis with the 































Figure 37: IKK inhibition abolishes TNF+IL1β-induced endothelial cell elongation. 
HUVECs were treated with a combination of TNF and IL1β in the presence of 10μM of IκB 
kinase (IKK) inhibitor. Control cells were treated with DMSO. Scale bar: 100 μm. Quantification 





In order to determine which regulators are involved downstream of NF-κB and ROCK 
signalling pathways in the rearrangement of endothelial cell shape, Western blot analyses 
was performed in HUVECs treated with the pro-inflammatory cytokines. It was initially 
speculated that the protein cofilin, an established factor that regulates the dynamic of F-
actin (169), could participate in the inflammation-induced cell elongation of HUVECs. 
The time-course analysis of cofilin phosphorylation shown in Figure 38 confirms this 
hypothesis. Cofilin became increasingly phosphorylated throughout TNF+IL1β 
stimulation, reaching its peak at 48 hours. Phosphorylation of cofilin is thought to inhibit 
its actin-depolymerizing activity (170), although this mode of regulation has been shown 
to be more complex that previously appreciated (171). Nevertheless, the phosphorylation 
of cofilin induced by the pro-inflammatory cytokines is consistent with the hypothesis 
that the activation of this cytoskeletal regulator may be responsible for the F-actin 
rearrangement observed in HUVECs. 
To further investigate the role of cofilin phosphorylation in endothelial cell elongation, 
cytokine-stimulated HUVECs were treated with ROCK and IKK inhibitors and analysed 
by Western blot. As shown in Figure 39, the increased phosphorylation of cofilin induced 
by TNF+IL1β was abolished in the presence of both inhibitors, suggesting a possible role 
of cofilin phosphorylation in the cytokine-induced elongation of HUVECs. However, the 
IKK inhibitor alone increased cofilin phosphorylation compared to that in control cells, 
even though it did not induce cell elongation. This data would then suggest that the 
phosphorylation of cofilin is correlated to cytoskeletal elongation but it may not have a 
causal role in the process. Further experiments would be required to assess the nature of 
this causality (i.e., blocking directly cofilin phosphorylation). 
The phosphorylation of VE-Cadherin was also examined, as it has been shown to play a 
role in the reorganisation of endothelial junctions and the increase in vascular 
permeability during inflammation (172). In HUVECs treated with TNF+IL1β the 
phosphorylation of VE-Cadherin at residue Y731 was increased, confirming the previous 
findings. In the presence of the elongation-blocking inhibitors Y27632 and IKK II 
however, the increased phosphorylation was not inhibited. These results suggest that VE-
Cadherin phosphorylation may not be necessary for the rearrangement of the actin 
cytoskeleton but independently required for adherens junction maintenance during 










Figure 38: TNF and IL1β induce cofilin phosphorylation in a time-dependent manner. HUVECs 
were treated with a combination of TNF and IL1β for 48 hours. Protein lysates were collected at the 
indicated time points and subjected to Western blot analysis with different antibodies. GAPDH was 
used as a loading control. Blot is representative of three independent experiments. Blot is 












Figure 39: Protein phosphorylation in cytokine-treated endothelial cells in the presence of 
chemical inhibitors. HUVECs were treated for 24 hours with a combination of TNF and IL1β in 
the presence of the Rho inhibitor Y27632 and the IKK inhibitor. Control cells were treated with 








5.2.4 Notch signalling role in inflammation-induced endothelial cell elongation. 
 
The cellular effects induced by the pro-inflammatory cytokines TNF and IL1β on ECs 
have been recently interpreted in the literature as a “mesenchymal transition”, mainly 
because of the elongated shape reminiscent of fibroblast-like cells (71, 156). However, 
this morphological change is also consistent with ECs acquiring a tip cell phenotype (see 
section 1.1.2 and Figure 2). During angiogenesis, endothelial tip cells are the leading cells 
that are located at the tips of vascular sprouts and are characterised by several functional 
and molecular changes (173). The angiogenic tip cell phenotype plays a crucial role 
during vascular development but can also be induced by inflammation in adult 
vasculature (174, 175). To determine whether the molecular changes in inflammation-
induced ECs reflect an angiogenic response, the expression of members of the Notch 
signalling was examined, as this pathway has a central role in the process (176). The 
qPCR analysis shown in Figure 40 indicated that when HUVECs were stimulated with 
pro-inflammatory cytokines the transcriptional activity of Notch-related genes was 
affected. HEY1, a transcriptional repressor which acts downstream of Notch, was 
significantly induced by TNF+IL1β, with a fold induction of mRNA level >20 compared 
to that in untreated cells. Furthermore, the gene expression of two Notch ligands, Jagged1 
(JAG1) and Delta-Like 4 (DLL4) were differentially regulated; JAG1 expression was 
increased around 5-folds by TNF+IL1β, while the mRNA expression level of DLL4 was 
downregulated by 4 folds. This regulation pattern was consistent with a recent report 
showing that the ratio of JAG1/DDL4 expression was an important mechanism for tip 
cell selection during angiogenesis (177). The increased expression of the JAG1 ligand by 
pro-inflammatory cytokines in HUVECs was further confirmed at protein level by 
Western blot (Figure 41). Taken together, these results show that TNF and IL1β activate 
Notch signalling in ECs and induce a differential regulation of two Notch ligands. This 
corroborates the hypothesis that the morphological and molecular changes observed in 










Figure 40: Gene expression analysis of Notch signalling members in cytokine-treated 
endothelial cells.  HUVECs were treated with either a combination of TNF and IL1β or left 
untreated. RNA from each condition was extracted 24 hours after treatment and analysed through 
quantitative RT-PCR. mRNA expression levels are represented as fold change relative to that in 
control (untreated) cells. All values were normalized with the expression levels of the 
housekeeping gene RPL13A and represent the mean ±S.D. (n=3). P-values were calculated using 







Figure 41: TNF+IL1β induced JAG1 expression in endothelial cells. HUVECs were treated 
with a combination of TNF and IL1β for 24 hours and protein lysates were analysed by Western 
blot with the antibody against JAG1. GAPDH expression was used as a loading control. Blot is 




To investigate whether the upregulation of JAG1 in ECs could contribute to the 
activation/maintenance of the TNF+IL1β-induced cell elongation via a paracrine 
signalling, JAG1 mRNA expression was blocked through siRNA and the morphology of 
HUVECs was examined. As shown in Figure 42, JAG1 siRNA totally abolished cytokine-
induced JAG1 upregulation.  However, cell culture images and the respective shape 
analysis shown in Figure 43 revealed that the cell elongation induced by TNF and IL1β 
was not affected by JAG1 siRNA. Therefore, these results indicate that the upregulation 
of JAG1 was not related to the cytoskeletal rearrangements of ECs triggered by pro-









Figure 42: Efficiency of JAG1 gene silencing in endothelial cells. HUVECs were treated with 
a combination of TNF and IL1β together with either JAG1-targeting siRNAs or non-targeting 
siRNAs as a control. RNA from each condition was extracted 24 hours after treatment and 
analysed through quantitative RT-PCR. The mRNA expression levels were represented as fold 
change relative to siRNA no-target. All values were normalized with expression levels of the 
RPL13A housekeeping gene and represent the mean ±S.D. (n=3). P-value was calculated using 













Figure 43: JAG1 gene silencing has no effect on cytokine-induced endothelial cell elongation. 
HUVECs were treated with either JAG1 siRNAs or non-targeting siRNAs as a control, together 
with a combination of the inflammatory cytokines TNF and IL1β (10µg/ml). Cell culture images 
were acquired 48 hours after treatment. Scale bar = 100µm. Quantification of cell elongation was 
performed on multiple images of each condition using ImageJ software (see section 2.7 for 





5.2.5 Effect of global inhibition of transcription and translation on HUVECs 
stimulated with pro-inflammatory cytokines 
 
One of the main functions of pro-inflammatory cytokines in the endothelium is the 
recruitment of leukocytes to the site of inflammation. This process is characterised by 
complex sequence of structural and molecular changes of ECs which are in turn regulated 
by several signalling pathways and gene expression programs (28, 161). 
In order to investigate whether the cytoskeletal rearrangements induced by 
proinflammatory cytokines were mainly due to gene transcription, or rather due to the 
post-translational modification of cytoplasmic proteins, HUVECs were stimulated with 
TNF and IL1β in the presence of Actinomycin-D and Cycloheximide, inhibitors of 
transcription and translation, respectively. Actinomycin-D is an antibiotic derived from 
bacteria that intercalate into DNA thus preventing the progression of RNA polymerases 
(178), while Cycloheximide is an inhibitor of protein synthesis that blocks the 
translational elongation in eukaryotic organisms. As shown in Figure 44, 24 hours 
Actinomycin-D treatment decreased the number HUVECs in the monolayer. When 
Actinomycin-D was added in the presence of TNF and IL1β there was a significant 
increase in cell death. This indicates that the transcriptional activation induced by 
proinflammatory cytokines could be necessary for the expression of essential anti-
apoptotic genes. Similar results were obtained when HUVECs were treated with 
Cycloheximide (Figure 45). Thus, investigating the individual contribution of the two 
processes (de novo transcription/translation versus post-translational modification of pre-
existing proteins) to the rearrangement of the cytoskeleton appears to be unfeasible using 
this strategy. More specific approaches, i.e. targeting specific transcription factors, would 


















Figure 44: Global inhibition of gene transcription in endothelial cells treated with 
proinflammatory cytokines. HUVECs approaching confluence were either stimulated with TNF 
and IL1β or left untreated, in the presence of the chemical inhibitor Actinomycin-D (1μg/ml). 
Cell culture images were acquired 24 hours after treatment. Scale bar: 100μm. Images are 












Figure 45: Global inhibition of protein translation in endothelial cells treated with 
proinflammatory cytokines. HUVECs approaching confluence were either stimulated with TNF 
and IL1β or left untreated, in the presence of the chemical inhibitor Cycloheximide (10μg/ml). 
Cell culture images were acquired 24 hours after treatment. Scale bar: 100μm. Images are 





5.2.6 Gene expression analysis of secreted proteins in inflammation-induced 
endothelial cells 
 
Besides the regulation of vascular permeability and the recruitment of immune cells from 
blood, ECs also have an active role in the remodelling of extracellular matrix (ECM) of 
the surrounding tissue, whose function is to provide the optimal environment for the 
progression and resolution of inflammation (174). At the molecular level, ECs secrete 
several ECM components when activated by pro-inflammatory cytokines, such as 
protease and collagens (179). Understanding the variety of these proteins and dynamics 
of their expression by ECs may give important insights into pathological conditions 
associated with the composition and turnover of ECM. 
To determine whether pro-inflammatory stimuli on HUVECs have significant regulatory 
effects on ECM proteins, the gene expression of ECM genes that were previously 
associated with fibrotic disorders was analysed by qPCR. Treatment with cytokines 
consistently downregulated the mRNA levels of ELASTIN and COL1A2 compared to 
that in the untreated cells, with negligible differences when TNF and IL1β were used 
alone or in combination (Figure 46). COL16A1 expression was upregulated by both 
cytokines, although its level in IL1β-treated cells was an order of magnitude higher than 
that in TNF-treated cells. TNF+IL1β treatment induced the highest upregulation of 
COL16A1 expression, indicating a synergistic effect of the two cytokines. Tenascin-C 
expression changes revealed a switch-on effect for this gene. The mRNA was 
undetectable in untreated cells and its cycle threshold (Ct) was given an arbitrary value. 
This transcriptional activation was preferentially induced by IL1β, as mRNA level was 
two orders of magnitude higher than that by TNF. No significant difference in Tenascin-
C expression was detected in the presence of both cytokines. Finally, the gene expression 
levels of MMP1 and LOX were not changed among the different conditions, while the 
mRNA expression of COL1A1, COL4A3 and COL22A1 was not detected.  
Taken together, these data indicate that pro-inflammatory cytokines differentially regulate 
the expression of ECM genes in ECs, which in turn may have important effects on how 




Figure 46: Gene expression analysis of ECM genes in cytokine-treated endothelial cells. 
HUVECs were treated with TNF, IL1β or a combination of the two cytokines for 24 hours and 
RNA samples were analysed by quantitative RT-PCR. The mRNA expression levels were 
represented as fold change relative to untreated cells. All values were normalised against the 
RPL13A housekeeping gene and represent the mean ±S.D. (n=3). ** P < 0.01, * P < 0.05; for all 





In this result section, the regulators of cytokine-induced EC shape elongation have been 
investigated. The main results are summarized in the following points: 
 
 TNF and IL1β synergistically induce gene transcription of the cytoskeletal 
regulator RND1. Blocking its expression does not impair EC elongation, 
indicating the RND1 is not involved in the phenotypic change 
 
 ROCK kinase mediates cytokine-induced EC elongation; however, shape change 
is not determined by the Rho GTPase-MLCK axis 
 
 NF-κB signalling controls EC elongation through IKK kinases 
 
 Notch ligand Jagged1 is induced transcriptionally by TNF and IL1β, but it is not 
involved in  morphological change of ECs 
 
 TNF and IL1β synergistically induce dramatic transcriptional upregulation of 

























5.4.1 Molecular mechanisms underlying shape elongation of ECs 
 
Inflammatory cytokines induce the transcription of a multitude of genes that are necessary 
to perform a variety of molecular events. Likely, several of those genes are necessary to 
modulate the cellular architecture of ECs. It was then sought to identify new 
inflammation-induced cytoskeletal regulators and the attention was focused on the Rho-
GTPase RND1, since it was previously shown to be upregulated by TNF in a published 
gene microarray study (161). Interestingly, this gene was also known to regulate actin 
reorganization and cell adhesion (162), but its role in ECs is currently not established. 
The transcriptional upregulation of RND1 was confirmed in HUVECs treated with TNF 
and IL1β (5.2.1). Furthermore, the expression was found to be further increased in the 
presence of both cytokines, which correlates with the synergistic effect of TNF and IL1β 
on cell elongation. However, siRNA-mediated blockage of RND1 upregulation did not 
affect TNF+IL1β-induced morphological changes. Thus, these results indicate that RND1 
is not involved in the inflammation-induced cell elongation of ECs. The magnitude of the 
gene expression induction is nonetheless indicative of potential functional role of RND1 
during inflammation. Emerging evidence suggests for instance that RND proteins are 
involved in the migration of neurons (180). Similarly, RND proteins may play a role in 
endothelial migration during angiogenesis. 
The signalling pathways related to the Rho-subfamily of GTPase were then examined 
since these small proteins, which include the founding trio Rho, Rac1 and Cdc42, are 
critical in the regulation of cell motility and cytoskeletal dynamics (181). Indeed, 
inhibition of ROCK, a serine-threonine kinase and downstream effector of RhoA, 
prevented the cell elongation of HUVECs induced by TNF+IL1β, consistently with a 
previous study (5.2.2) (146). The blockage of ROCK activity also resulted in the 
formation of thin cellular protrusion, probably due to the altered balance of actin 
regulators and/or off-target effects of the inhibitors. Furthermore, inhibitors targeting Rho 
members (C3 transferase) or the downstream ROCK effector MLCK (ML7), failed to 
prevent the TNF+IL1β–induced cytoskeletal rearrangements. These results thus suggest 
that the ROCK kinase is involved in cell elongation of HUVECs, but it may participate 
in a signalling axis different from the canonical Rho-MLC pathway. 
NF-κB is the common transcription factor activated by different inflammatory cytokines 
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and its role has been linked to many diseases, including cancer and EMT (145, 167). Time 
course analysis on TNF+IL1β-treated HUVECS showed that the NF-κB inhibitor IκBα 
was rapidly degraded upon stimulation and returned to normal levels within 2 hours, 
indicating that the transcriptional program induced by TNF and IL1β is activated in an 
early and short time window (5.2.3). Furthermore, the blockage of the NF-κB upstream 
kinases IKK resulted in reduced cell elongation of HUVECs, consistently with recent 
studies reporting the involvement of NF-κB in morphological rearrangements of ECs 
(157, 182, 183). These results leave open the possibility that the transcriptional activity 
of NF-κB and/or the cytoplasmic function of the upstream IKK complex are responsible 
for actin reorganization of inflammation-induced ECs. The latter appears more plausible 
given that the morphological changes are induced rapidly and thus may not involve de 
novo transcription. Moreover, recent  research has shown a role of IKK kinases in the 
NF-κB-independent signalling pathways (184). For instance, IKKβ has been shown to be 
involved in Tumour angiogenesis through the mTOR pathway (185). 
The ability of ROCK and IKK inhibitors to prevent cell elongation in HUVECs was 
subsequently exploited to identify molecular effectors involved in the cytoskeletal 
rearrangements (5.2.2). Phosphorylation of cofilin, an actin-regulating protein (169), was 
increased upon TNF+IL1β treatment but the phosphorylation status was not altered in the 
presence of ROCK and IKK inhibitors, thus excluding its involvement in the observed 
morphological changes. Similar results were also observed with the junctional protein 
VE-Cadherin, whose phosphorylation correlated with but not determined the TNF+IL1β-
induced elongation of ECs. 
Taken together, these results suggest that both Rho-GTPase and NF-κB signalling 
pathways are involved in cytokine-induced cytoskeletal rearrangements of human ECs. 
The crosstalk between Rho and NF-κB in the shape changes of ECs would be an 
interesting possibility to test, since their interaction has been shown to be involved in 
cellular processes such as motility and matrix remodelling during chronic inflammatory 
diseases (186).  
 
5.4.2 Angiocrine functions of endothelial cells in disease 
 
Within the cardiovascular system, the EndMT has been described in vivo as a cellular 
source of dysfunctional cells: collagen-producing fibroblasts in cardiac fibrosis and 
contractile smooth-muscle cells in atherosclerosis and vein graft remodelling (54, 71). 
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Although the in vivo evidence for this pathogenic role has been recently challenged, as it 
will be discussed in the next paragraph, it may be worth considering other possible 
mechanisms through which the endothelium may contribute to the emergence of chronic 
cardiovascular diseases. An emerging research subject is the so-called vascular niche, 
namely the microenvironmental set of signals used by ECs to communicate with other 
cell types. These signals, which have also been termed “angiocrine factors”, include 
different molecules such as cytokines, growth factors, proteases and miRNAs. Angiocrine 
factors have been shown to contribute to a broad range of physiological and pathological 
processes such as fibrosis, cancer and stem cell maintenance (187-189).   
In light of the importance of the above-mentioned mechanisms, the gene expression of 
several extracellular-matrix proteins was measured in HUVECs treated with TNF and 
IL1β (5.2.6). Results showed that mRNA levels were changed for several proteins, thus 
suggesting that ECs may qualitatively influence the remodelling of the surrounding 
extracellular matrix. For instance, COL1A2 and elastin were downregulated, whereas 
COL16A1 and Tenascin-C were upregulated. Interestingly, Tenascin-C gene expression 
was literally switched on, as in most experiments its expression was not detected in 
untreated cells. The activation seemed to be preferentially induced by IL1β since its 
expression was significantly higher compared to TNF-treated cells. As far as one can tell 
from the literature, the molecular signalling leading to Tenascin-C gene expression has 
not been previously identified in ECs. 
Tenascin-C is large extracellular glycoprotein which has been found to play disparate 
roles in both embryonic development and disease (190). It is absent in normal tissues but 
it is rapidly reactivated during tissue injury. Furthermore, Tenascin-C has been suggested 
to play critical roles in cardiac and arterial remodelling (191). Interestingly, Tenascin-C 
was originally described to be involved in EndMT during the development of the heart 
valves. This protein was in fact found to be deposited in the extracellular space of the 
endocardium prior to endothelial cell activation. It may therefore be tempting to speculate 
that this protein, during inflammation, could be secreted in the extracellular space at the 
onset of tissue injury to provide a supporting guide for the migration of pro-angiogenic 
ECs. Alternatively, endothelial-secreted Tenascin-C may constitute a paracrine signal for 
the activation of fibroblasts during fibrotic remodelling. 
 




Genes belonging to the Notch signalling pathway were found to be differentially 
regulated by inflammatory cytokines in HUVECs (5.2.4). Jagged 1 (JAG1), the ligand of 
the receptor Notch-1 which has been linked to Alagille syndrome and the development of 
the cardiovascular system (192), was indeed found to be induced by TNF+IL1β treatment 
at both mRNA and protein level. This result is consistent with a previous study showing 
that TNF induces JAG1 in an NF-κB-dependent manner (193). Furthermore, the gene 
expression level of DLL4, another Notch ligand, was significantly reduced while HEY1, 
a Notch-related transcription factor, was upregulated by the inflammatory cytokines. It 
may be worth considering these results in light of new reported functions of Notch 
signalling in ECs. Indeed, the balance between JAG1 and DLL4 expression has been 
recently shown to control sprouting angiogenesis in the context of tip and stalk cell 
selection (177). DLL4 expression in tip cells is known to induce Notch signalling and 
suppress a tip cell phenotype in adjacent stalk cells, while JAG1 was instead shown to 
antagonize DLL4-Notch signalling and therefore to act as a pro-angiogenic ligand. The 
inflammatory stimulus is therefore thought to be able to dynamically modulate the 
angiogenic response of ECs through the regulation of the balance of these two opposing 
ligands. In agreement with this, another study showed that TNF-induced JAG1 
upregulation in ECs induced a tip-cell, migratory phenotype, with the duration of the 
inflammatory stimulus representing a critical factor for a successful angiogenic response 
(175). In summary, these findings indicate that the inflammation-induced Notch-mediated 
genetic response activated in processes such as wound healing, enables ECs to expand 
toward an angiogenic stimulus and to regenerate the vasculature.  
It is also interesting to note how the angiogenic remodelling of blood vessels during 
inflammation and tissue repair shares many similarities with the EndMT; the endothelial 
tip cells that guide the front of an angiogenic sprouting are in fact highly polarized, are 
rich in filopodia and present a behaviour characterised by increased migratory and 
proteolytic activity, since tip cells need to explore and invade the surrounding matrix 
(194). Although these features are mesenchymal in nature, it seems incorrect to frame the 
behaviour of endothelial tip cells as an EndMT, as it has been suggested (133): firstly, the 
angiogenic migration of endothelial tip cells is collective; it is in fact coordinated among 
several cells of the blood vessel. Secondly, endothelial tip cells do not normally become 
individualized mesenchymal cells, namely they do not lose contact with other ECs. 
Thirdly, the downregulation of VE-Cadherin by transcriptional repressors such as Snail1 
and 2, which would represent the genetic pillar of a true EndMT, has not been 
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unequivocally demonstrated in vivo (see section 1.3.2.4).  In agreement with these 
observations, a recent work looking at the role of SNAI2 in the sprouting of HUVECs 
described the angiogenic phenotype as a partial EndMT, as SNAI2 was not found to 
regulate the transcription of  VE-Cadherin (195, 196).  
In conclusion, these observations suggest that the EndMT does not describe correctly the 
cellular behaviour of ECs during angiogenesis. Nonetheless, the tip-stalk concept 
underlying inflammation-induced angiogenesis may be a valid alternative to the EndMT 





Chapter VI – Conclusion: final considerations 
 
 
6.2 Project Background 
 
Fibrosis is a scarring process characterised by the excessive production of ECM, which 
changes the architecture of organs and impairs their function. Fibrosis underlies the 
development of several chronic diseases in many organs, such as heart, lung, kidney, liver, 
skin, intestine and bone marrow (197). The heart is an efficient pump formed of different 
cell types. Cardiomyocytes, the cells responsible for muscle contraction, account for 
almost one third of all cells. The other two thirds are non-myocyte cells that comprise 
ECs, vascular smooth muscle cells and fibroblasts. All these cell types are surrounded 
and held together by the ECM, which is like concrete in a wall of bricks. The balance of 
each cellular constituent is fundamental to maintain the correct function of the heart. The 
accumulation of fibrillar collagen in the ECM renders the heart tissue stiffer and less able 
to cope dynamically with mechanical forces, resulting in adverse cardiac events such as 
cardiac failure (198). Myocardial fibrosis is among the main causes of diastolic 
dysfunction and accompanies the development of most heart diseases (199). There are 
currently no specific anti-fibrotic therapies and more research is needed to define the 
molecular and cellular features of this pathological process.  
From a physiological point of view, myocardial fibrosis progresses as a maladaptive 
regenerative reaction aimed at replacing dying muscle cells in the tissue following 
myocardial ischemia (198). However, fibrosis also occurs in response to the overgrowth 
of cardiomyocytes in hypertrophic cardiomyopathy (HCM) caused by genetic mutations 
in sarcomere proteins (200). Nevertheless, irrespective of the diverse pathophysiologic 
causes of myocardial fibrosis, research now is focused on the common cellular effectors 
of this complex disease: the fibroblasts.    
It is known since the work of the German pathologist Rudolph Virchow in 19th century 
that fibroblasts are the predominant source of the ECM in fibrosis (197). Collagen is 
secreted by fibroblasts that acquire increased proliferative and biosynthetic activities. 
They are thus defined “activated fibroblasts” or myofibroblasts, since they express the 
contractile protein αSMA (201). What is still unknown is the source of myofibroblasts in 
cardiac fibrosis. The highly heterogeneous nature of this cell type, which displays 
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different subpopulations even in the same organ, and the lack of univocal markers, has so 
far hampered the clear identification of their origin (202). Several studies have so far 
identified multiple sources of fibroblasts in the cardiac tissue; the traditional view holds 
that they accumulate through proliferation of the resident fibroblasts (203), but recent 
evidence has suggested additional sources (204): bone marrow cells and endothelial cells 
(54) (see Figure 47 for an illustrative summary). 
Fibroblasts are thought to originate from ECs through the EndMT process, which is 
defined as the transdifferentiation of ECs into mesenchymal cells. ECs form the internal 
lining of blood vessels. They display an apical-basal polarity and express specific junction 
proteins (VE-Cadherin, Pecam-1) that allow them to closely bind together (205). During 
the EndMT ECs loose these characteristics and acquire a mesenchymal phenotype, which 
includes a front-rear polarity, a spindle-shaped morphology and increased migratory and 
contractile properties (206). These changes are underlined by the downregulation of 
endothelial specific proteins and the concomitant expression of mesenchymal markers, 
such as N-Cadherin, Fibroblast Specific Protein-1 (FSP1) and αSMA (207). The set of 
molecular processes occurring in EndMT are closely related to the epithelial-
mesenchymal transition (EMT), and the EndMT has been indeed categorised as a 
specialized form of EMT. EMT is a fundamental biological process involved in the 
formation of tissues and organs during embryogenesis and its reactivation in adulthood 
leads to a wide range of diseases, including fibrosis and cancer (35). 
EndMT was originally described in the formation of heart valves during early 
cardiogenesis. In the primitive heart tube, the ECs of the atrioventricular canal region 
delaminate and transdifferentiate into mesenchymal cells, which invade the cardiac jelly 
between the myocardium and endocardium to form the endocardial cushions, the 
structures that develop into heart valves (53). This developmental EndMT is thought to 















Figure 47: Schematic illustration of the potential cellular sources of collagen-producing 
myofibroblasts during cardiac fibrosis. Activated fibroblasts (myofibroblasts) contribute to 
cardiac fibrosis through the secretion of collagen. The traditional view that myofibroblasts derives 
uniquely from proliferation of resident fibroblasts has been recently challenged by studies 
showing that bone-marrow cells and endothelial cells (via EndMT) significantly contribute to 





6.2 EndMT in adult tissues: a theory stabbed in the heart? 
 
Recent studies have linked the EndMT to different pathologies. For instance, Maddaluno 
et al. reported the involvement of EndMT in Cerebral Cavernous Malformation (CCM), 
a form of vascular dysplasia in which blood vessels in the brain present an irregular 
structure (209). This condition causes vascular leakage and fatal brain haemorrhage. 
Maddaluno et al. showed that ECs in these vascular lesions expressed a set of 
mesenchymal (Slug, N-Cadherin, αSMA, Id1) and stem cell markers (Sca1, CD44). 
Furthermore, ECs extracted from mouse brains indicated that this altered gene expression 
was dependent on TGFβ and BMP signalling. The authors interpreted their findings as an 
ongoing EndMT process. Similarly, Cooley et al. implicated the EndMT in the neointimal 
hyperplasia that occurs during vein graft remodelling (72). To demonstrate this, the 
authors used the Tie2-Cre mouse model, the lineage tracing system used to demonstrate 
EndMT in previous publications (see section 1.3.2.3). The authors concluded that half of 
the cells composing the neointimal lesions were derived from ECs and that this process 
was mechanistically driven by the TGFβ-Smad2/3 pathway. Additionally, two recent 
papers reported the EndMT in pulmonary hypertension; Ranchoux et al. showed in both 
human and animal samples the cellular co-localization of VE-Cadherin and αSMA, while 
Good et al. observed that 5% of cells lung cells in pulmonary hypertension patients were 
positive for both vWF and αSMA (210, 211) 
 
The in vivo experimental technique that can conclusively demonstrate the ontogeny of 
cells in an organism is the lineage-tracing model. Such evidence was firstly provided in 
2007 by the seminal paper by Zeisberg et al., who used the Tie1-Cre model (133). How 
accurate is their model? The fundamental assumption made was that Tie1 is specifically 
expressed by ECs. A recent study challenged this very assumption and refuted in toto the 
idea that accumulating fibroblasts in cardiac fibrosis derive from ECs (212). First, Moore-
Morris et al. noted that FSP1 was not a fibroblast-specific marker, for it is also found to 
be expressed in immune cells, ECs and vascular smooth muscle cells (213, 214). Second, 
the authors observed that the Tie1 gene also lacks specificity as it was reported to be 
expressed in immune cells (215). To overcome these limitations, Moore-Morris et al. used 
an updated lineage tracing strategy in which fibroblasts were marked through a 
collagen1a1-GFP enhancer. They thus showed that pressure overload-induced cardiac 
fibrosis activated the proliferation of two resident fibroblast lineages. Furthermore, they 
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ruled out the occurrence of EndMT through VE-Cadherin-Cre mouse lines. In agreement 
with the findings of Moore-Morris et al., Ali et al. identified two distinct lineages of 
fibroblasts in the heart through an in-depth FACS-based analysis (216). The authors found 
that both fibroblast lineages contributed equally to pressure-overload fibrosis, thus ruling 
out the occurrence of an alternative EndMT process.  
Together, the findings of Moore-Morris et al. and Ali et al. findings seriously question the 
existence of an EndMT process in cardiac fibrosis. Similarly, the occurrence of EMT in 
kidney and liver fibrosis has also been vehemently questioned (217-219). At the heart of 
the controversy are the specificity of FSP1 and αSMA as markers of myofibroblasts and 
the lack of anatomical and ultrastructural evidence directly demonstrating the ongoing 
EMT process. Most in vivo studies have in fact provided static and indirect evidence that 
provides little information about the dynamic nature of the EMT. In this regard, it may 
worth pointing out that the involvement of both EndMT and EMT in fibrotic diseases was 
demonstrated in vivo using the same experimental strategies developed in laboratory of 
Eric Neilson in the early 2000’s (1.2.4) (50, 51). Those findings have not been thoroughly 
reproduced by independent labs with different methodologies. 
Adding to the inherent inconsistencies of the EndMT concept, the in vitro evidence 
supporting EndMT also appear to be weak, as most studies used ECs to indirectly 
corroborate major in vivo findings. No studies have in fact thoroughly analysed the 
EndMT process from a pure molecular cell biology perspective. As reviewed in the 
introduction (see section 1.3.2.2 and Table 1), initial studies provided in fact 
circumstantial evidence, such as the upregulation/downregulation of selected markers or 
the appearance of a spindle-shape morphology. The apparent readiness of human ECs to 
become mesenchymal-like cell, as it was spectacularly demonstrated by Medici et al. (67), 
has so far received little if any confirmation.  
In the cancer field, the EMT still represents the prevailing view of how cancer cells 
become able to metastasize. However, EMT in cancer is not immune from criticism as 
well (220-222). Critical issues regard the fact that the complexity of the EMT process is 
often reduced to too simple linear mechanism (TGFβepithelial marker 
downmesenchymal marker upcancer). This carries the risk of oversimplifying the 
concept leading to an “EMT-centric” view, where every single cellular event involving 
for instance suppression of adhesion, shape change and motility, could be interpreted as 
an EMT, even though they belong to completely different cellular processes (223).  The 
EndMT, as a subtype of EMT, may have suffered similar issues but, in addition, it is based 
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on much less molecular and cellular evidence.   
 
In conclusion, in light of the new updated lineage-tracing in vivo models, the inconsistent 
literature regarding endothelial transdifferentiation in vitro, and the results obtained in 
HUVECs in the present project, it may seem reasonable to consider the EndMT a wrong 
hypothesis. Nonetheless, the plasticity of the endothelium and its largely unexplored 
interaction with the immune system and other tissues during inflammatory condition are 
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